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ABSTRACT 
 
The use of targeted ligands to deliver radioisotopes directly to tumor cells is a promising 
therapeutic strategy. Because of the short path length and high LET of alpha particles, targeted 
alpha particles are ideal for treating metastatic disease while minimizing damage to non-targeted 
tissues. However, clinical methods for determining 3D radiation dosimetry in patients with 
multiple metastatic lesions are needed to support clinical translation of novel targeted alpha 
particle therapies for personalized treatment, especially in patients that have previously received 
radiotherapy. Recently interest in novel radiopharmaceutical development has grown 
significantly. However, compared to external beam radiation therapy, progress in customizing 
radiopharmaceutical treatments specific to the patient has remained stagnant for decades. 
Currently, therapies are given using fixed dose administrations and dosimetry is performed using 
outdated simplistic representations of a standard human. The potential benefits of targeted alpha 
therapies cannot be taken advantage of until pretreatment planning is employed to optimize each 
patient’s therapy on an individual basis. Dose response relationships need to be analyzed post-
treatment to assess tumor control probabilities and normal tissue complications. With new 
developments in medical imaging and instrumentation, along with the continuously increasing 
computational power available, personalized targeted alpha therapies can be achieved. 
In this work, a novel targeted alpha therapy for treatment of metastatic uveal melanoma,
 
225
Ac-DOTA-MC1RL, is developed and thoroughly tested pre-clinically. The therapy showed 
 xi 
rapid eradication of tumors with no normal tissue toxicity with a single administration. Radiation 
detection instrumentation is improved upon by developing a method to more accurately quantify 
radioactivity for administration, biodistribution, pharmacokinetics, and dosimetry. A voxel-based 
Monte Carlo dosimetry methodology is developed using a novel companion imaging agent in 
both phantom and in vivo pre-clinical imaging studies. From these studies, a clinically 
translatable workflow is described and tested. 3D dosimetry calculations were performed 
enabling volumetric dose analysis for the novel therapy.
1 
 
 
 
CHAPTER ONE:  
INTRODUCTION 
 
1.1 Overview 
 Advances in the understanding of molecular characteristics of cancerous cells have paved 
the way for targeted radiopharmaceutical therapy. Identifying a malignant target and designing a 
vehicle to deliver high doses of radiation has become a promising modality to treat cancer. 
Recently, interest in using alpha emitting radioisotopes to selectively destroy the DNA of cancer 
cells has increased. This is due to their short path length and large linear energy transfer. The 
range of an alpha particle is three to six cell lengths and only one cell traversal is needed to cause 
irreparable damage. Ideally the drug will bind to the targeted cells without causing damage to 
surrounding healthy cells.  
The use of radiation to treat cancer is well established and has been a strategy for over 
100 years. During this time, external beam therapy has become the most common form of 
radiation therapy. Advances in geometrical tumor targeting, treatment planning, optimization, 
dose calculation, delivery, guidance, verification, and disease control have made external beam 
therapy the standard delivery of therapeutic radiation. For a modern external beam radiation 
treatment, the radiation therapy team may spend weeks designing and tailoring the optimal plan 
by choosing variations in beam type, energy, treatment time, and geometry. Radionuclide 
therapy has been a cancer treatment approach since the 1940’s with the use of 131I for the 
 2 
treatment of thyroid disease. However, patient specific treatment design and workflow 
innovation has severely lagged behind the advancements made in external beam therapy. In 
radionuclide therapy it is common to prescribe fixed-dose non-specific administrations to all 
patients. This leads to “consciously choosing that patients be treated with a lower standard of 
care than external beam patients
1.” These fixed administrations are based on calculations 
performed on a stylized fixed geometry model of a standard human. Since radionuclide therapies 
are systemic, toxicities are not only a function of administration but also functional and 
anatomical variations. 
With the growing interest in developing new radiopharmaceuticals that target specific 
cells which previously could not be optimally treated, the field has made progress in entering the 
era of personalized medicine. Developments in modeling biological endpoints and 
pharmacokinetic analysis have led to the emergence of patient specific internal dosimetry. 
Improvements in quantitative imaging and computational power have led to work in modeling an 
individual patient’s anatomy and physiology and computing the 3D radiation dose distribution 
specific to each patient using Monte Carlo. 
 
1.2 Objectives 
In this work, a novel targeted alpha therapy is developed and tested. The principal goal is 
to develop a methodology for 3-dimensional patient specific internal radiation dosimetry for the 
targeted alpha therapy that can be implemented clinically. The methodology should be quick, 
straight forward and accurate. The workflow is initially developed using phantom studies and 
then it is applied to a mouse experiment. Patient specific models are created using computed 
tomography (CT) and spatial and temporal activity distribution maps are created using single 
 3 
photon emission tomography (SPECT). Dosimetric calculations are performed using the Monte 
Carlo N-Particle (MCNP) package. As a benchmark, the results of the dosimetric workflow will 
be compared to conventional internal dosimetry methods.  
 
1.3 Outline 
 This work is structured into six chapters. Chapter 2 starts by describing the radiation 
biology and mechanism of action of alpha particles. The chapter continues with a summary of 
the clinically relevant alpha emitting radionuclides. The final portion of this chapter is a 
summary of internal radiation dosimetry methods. 
 Chapter 3 describes the identification of an issue that is commonly overlooked in targeted 
alpha therapy development. Many alpha emitting radionuclides have complex decay chains 
consisting of alpha emitting daughters. The radioactivity of these daughters must be quantified 
for a complete analysis of the therapy. If the daughter species emit gamma rays, a scintillation 
detector can be used and spectrum analysis can be performed to separate the daughter activities. 
Scintillation detectors however suffer physical limitations with increasing activity. Therefore a 
method is described that corrects the scintillation detector’s readings at higher activities using 
Monte Carlo to permit the analysis of daughter products. 
Chapter 4 describes the preclinical testing of the novel metastatic uveal melanoma 
targeted alpha therapy. The chemistry, biology, and physics considerations are presented. The 
physics portion includes the description of the indirect measurement of alpha activity for 
administration analysis, blood pharmacokinetics, biodistribution, and conventional radiation 
dosimetry. 
 4 
Chapter 5 describes the development of a multi-compartment pharmacokinetic model for 
the targeted alpha therapy and a derivative that was developed and tested. The model can be used 
to implement patient specific therapy by optimizing administration activities from simulated 
biodistribution obtained from imaging and/or blood and urine samples.   
Chapter 6 describes the development of the voxel-based 3D internal dosimetry 
methodology. A companion imaging agent to the targeted alpha therapy is developed and tested. 
Phantom studies are conducted to develop the image-to-Monte Carlo conversion algorithms. 3D 
absorbed dose is generated for both the imaging agent and the therapeutic agent in mice and 
validated by comparing to conventional methods 
Chapter 7 summarizes the results of previous chapters. 
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CHAPTER TWO: 
BACKGROUND 
 
2.1 Mechanism of Action 
Since the discovery of radioactive materials, the effect of radiation on the properties of 
matter has been of significant interest in the disciplines of material science, geology and 
astrophysics. For example the first large-scale effect of radiation on solid material was observed 
by E.P. Wigner from exposure to a nuclear fission reactor and was thus named the Wigner effect, 
or "Wigner’s disease".2 Since then, the large spread of medical technology involving sources of 
ionization radiation 
3
 and the development of nuclear weapons have caused a spike in studies of 
the effect of radiation on living tissue. That work increased our understanding of the concept of 
radiation risk and created new fields of scientific study, for example, radiation health safety, 
radiation dosimetry, and radiation oncology.       
Because of the high energy of alpha particles and stochastic nature of ionization 
radiation, their effects may be observed on all levels of a biological system. Any molecule, cell, 
tissue or organ can display alpha decay radiation damage and such damage can be localized, or 
occur throughout the entire body of any multicellular organism.
4
      
The first step in producing radiation effects is the generation of a primary recoil atom and 
alpha particles by a radioactive decay. Such events take place very rapidly in much less than 1fs.
5
 
In the case of alpha decay of radiopharmaceutical isotopes of interest, the average kinetic energy 
 6 
per recoil atom is ~100 keV, and the average kinetic energy deposited within the range of a 
single alpha particle is on the order of 5 MeV. It is clear that the relatively high levels of energy 
deposited by the combination of the fast moving heavy ions and high energy alpha particles can 
cause large amounts of damage to solid matter. There are many methods to estimate the effect of 
radiation in solid materials, i.e. the stopping power theory based on Coulombic interactions, 
molecular dynamics, transport theory, etc.  However, unlike solid materials, biological tissues do 
not consist of solid crystalline structures, and this significantly increases the complexity of 
estimating the effects of alpha decay (as well as other ionization radiations), making the 
application of the aforementioned methods impossible or extremely difficult numerically. To 
overcome such limitations, a semi-quantitative approach has been applied. First, the biological 
effects observed in irradiated subjects were separated into one of two categories
4,6
: Deterministic 
effects, which have a practical threshold absorption dose below which effects are negligible or 
not evident; and stochastic effects, where the relationship between dosage and severity of effect 
is either less evident or absent. 
Maintaining the integrity of many different types of macromolecular structures is 
important to cell viability and all cellular organic molecules are subject to damage by ionizing 
radiation. However, the genomic DNA molecules are considered to be the most critical target for 
the biological effects of ionizing radiation because intact DNA is required for cellular 
replication, and damaged but improperly repaired DNA can result in fixation of genetic 
mutations that can affect normal cellular function and viability.
7
 Ionizing radiation interacts with 
DNA either by directly transferring energy to the biological material or indirectly by creating 
reactive free radicals from the radiolysis of water. These interactions result in damage to the 
DNA structure as a result of broken covalent bonds. Linear energy transfer (LET) is an approach 
 7 
to describe the spatial distribution of ionization and excitation produced by direct or indirect 
effects of different types of radiation along a linear path.
8
 Alpha particles are high LET radiation 
because they create dense ionizations and excitations in matter due to coulombic interactions 
with atoms. Being a heavy charged particle, an alpha particle will continuously slow down along 
its track with minimal deflection. Through the process of slowing down, the interaction cross-
section towards the end of travel increases, resulting in increased LET, which is known as the 
Bragg Peak.
9,10
  
Relative biological effectiveness (RBE) is the ratio of the dose of a reference radiation 
and the dose of a test radiation that produces the same biological effect. Some of the most 
common biological effect measurements are necrotic and apoptotic (programmed) cell death, 
DNA damage, chromosomal aberrations and genetic mutations. The RBE of alpha particles can 
range from 3.5 to 4 for cell killing, 6 to 12 for mutation, and 10 for cell transformation.
8
 As a 
comparison, the RBE for low LET electrons and photons is 1. 
An important biological endpoint is cell killing. Damage to cells can be classified as 
either sub-lethal events or lethal events. Sub-lethal events are due to the accumulation of damage 
that has potential to be repaired, typically as a result of exposure to lower doses, and lethal 
events typically result from irreparable damage due to exposure to higher doses.
4
 The ability to 
repair these events is seen as a shoulder on the cell survival curve and is characteristic of low 
LET radiation (Figure 1).
11
 A single event of high LET radiation can be lethal. The cell survival 
curve for a lethal event does not have a shoulder, indicating the inability to repair.
12
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Figure 1. Survival of a human kidney T-cell culture irradiated with ionizing particles of 
different kinds: 1) particles with E= 2.5 MeV, LET=165 keV/m; 2) particles with E=25 MeV, 
LET=25 keV/m; 3) deuterons with E=3.0 MeV, LET=20keV/m;  4) X-rays with E=20 keV 
and LET=6 keV/m; 5) X-rays with E=250 keV and LET=2.5 keV/m;  and 6) particles with 
E=2.2 MeV, LET=0.3 keV/m. This figure and legend were reproduced from Kudryashow, 
Y.B., Radiation Biophysics (Ionization Radiation). Nova Science Publishers Inc., 2006. 
 
The DNA double strand break is the most biologically significant type of damage, which 
occurs as a result of two single strand breaks in close proximity or a rupture of the double strand 
at the site of interaction.
13
 Cell survival is highly dependent on the spatial distribution of double 
strand breaks.
8
 Given the same dose, high LET radiation can create up to four times more double 
strand breaks than low LET radiation. Also, the formation of high LET double strand breaks are 
more complex compared to low LET in that they are less randomly distributed and form 
clustered DNA damage to multiple base-pairs.
9
 It has been widely accepted that high oxygen 
levels play a large role in a cell’s sensitivity to ionizing radiation and, hence, tumor hypoxia is an 
established factor in resistance to radiation therapy.
14
 This is due to enhancement of free radical 
production by the presence of oxygen. Free radical production occurs as a result of indirect 
action, or low LET interactions. Since alpha particles interact directly with the DNA, the level of 
 9 
oxygen becomes irrelevant, hence, eliminating a major mechanism of resistance to therapy.
4
 See 
Figure 1. 
After exposure to radiation that results in DNA damage, the cell cycle can be stopped at 
cell-cycle checkpoints which allow the cell to repair the damage via multiple repair mechanisms 
in order to preserve genomic integrity.
13
 In the case of irreparable damage, the cell will 
eventually undergo cell-death by apoptosis or necrosis. The two main repair mechanisms of 
double strand breaks are homologous recombination and non-homologous end joining. 
Homologous recombination occurs in the late S and G2 phases of DNA synthesis where an intact 
DNA template is available, resulting in a more efficient and high fidelity repair. Non-
homologous end joining occurs throughout the cell cycle but is the only means of repair in G1 
and early S phase. In this error prone repair method, DNA ends are rejoined with no sister 
template.
12
 In this case chromosomal aberrations can occur as a result of recombining incorrect 
DNA ends, i.e. combining a loose end to some other molecule, and truncation of ends. If 
incorrect repair occurs prior to DNA replication, these errors can be replicated in daughter DNA 
which can lead to mitotic cell death or can lead to the generation of genomic mutations without 
cell death.
12 
There is also the situation where double strand breaks are not repaired and the 
dividing cell enters mitosis, leading to mitotic catastrophe and eventual cell death. A higher 
proportion of double strand breaks remain un-rejoined after exposure to high LET radiation.
8
 
When it comes to damage from high LET alpha particles in close proximity to the cells being 
irradiated, the main radiobiological effect is complex and irreparable DNA damage resulting in 
cell death by either apoptosis or necrosis. 
In the last few years, successful attempts have been made to explain the bystander 
effect.
14,15
 The bystander effect is defined as effects that are observed in cells that have not been 
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directly irradiated following the irradiation of other nearby cells. Two mechanisms were 
proposed, one is the transfer of genomic instability through p53-mediated pathways and the other 
suggests that irradiated cells secrete cytokines or other factors that transit to other cells that were 
not irradiated and signal increased levels of intracellular reactive oxygen species.
16
 One of the 
defined sub-classes of bystander effect is the “abscopal effect,” in which radiation treatment of a 
tumor propagates to tumors outside the irradiated volume.
16
  A more recent publication 
demonstrated an effect that might explain the abscopal experience.
17
  It was demonstrated that 
alpha-particle treatment of prostate cancer cells generated an adaptive antitumoral immune 
response, as has been previously reported for other forms of radiation. The combination of 
bystander effects and the abscopal (likely immune) response in vivo are potential mechanisms of 
efficacy for tumors that are not avid for the targeted α-emitter radiotherapy in a patient with 
heterogeneous target expression. 
 
2.2 Alpha Emitting Radionuclides 
Using radiation as a method of cancer therapy requires delivering the maximum dose to 
the tumor while minimizing dose to healthy tissues. Targeted radionuclide therapy is 
advantageous in that it seeks molecular and functional targets within patient tumor sites.
18
 Beta 
emitting radionuclides (
90
Y, 
131
I, 
177
Lu, 
186
Re) are used for cancer-targeted therapy but have 
problems with cross fire irradiation of normal tissues due to their relatively long range in tissue 
which is in the range of 0.5-12 mm. In contrast, alpha particles deposit higher energy over a 
much shorter range (40-90 µm), potentially causing higher cytotoxicity to tumor cells while 
delivering a lower dose to normal adjacent tissues.
19
Alpha emission is the process by which an 
unstable nucleus ejects a highly energetic heavy charged particle consisting of two protons and 
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two neutrons. Alpha particles have a higher LET (100keV/µm) compared to beta particles 
(0.2keV/ µm) which results in dense ionization along its track in matter. The short range of alpha 
emission provides specificity to the target cell population with minimal effect on surrounding 
normal cells, and the high LET leads to a high frequency of irreparable DNA double strand 
breaks.
7
 This limits cytotoxic effects to within a small distance from the location of decay. It has 
been estimated that only one cell traversal by an alpha particle track is necessary to kill the cell 
while thousands of beta traversals are required for the same effect.
20
 Because of the long range of 
beta particles and the need of a high number of hits for cell killing, a large portion of the dose 
deposited is outside of the intended target. Hence, beta-emitting radionuclides are typically used 
for targeted treatment of non-solid or circulating types of cancer, i.e. leukemias and lymphomas, 
where target cells are not stationary in order to minimize damage to surrounding normal tissues. 
Regardless, use of alpha particles for targeted treatment of circulating disease could be an 
improvement due to potentially reduced damage to normal tissues. Use of targeted alpha particle 
therapy has been considered for killing isolated cancer cells in transit in the vascular and 
lymphatic systems, in regressing tumors by disruption of tumor capillary networks and in 
treatment of micrometastatic foci.
21
 In particular, targeted alpha particle therapy may be ideal for 
treatment of solid metastases as the short range will primarily kill tumor cells with little 
deleterious impact on surrounding normal tissue. Additionally, heterogeneity of target expression 
has been observed within a given tumor or metastasis
22
 and this is thought to be a mechanism of 
developing resistance to targeted therapies, where non-target expressing cells survive treatment 
and clonally expand into a resistant population. In this case, alpha emissions from a targeted cell 
will serve to kill surrounding untargeted cells within the effective range, potentially reducing the 
development of resistance.  
 12 
A number of factors need to be considered in choosing an alpha emitting radionuclide for 
therapy. These include proper nuclear characteristics, ease of radiochemical incorporation, 
specific activity, synthesis yields, chemical and biological stability, availability, and cost.
19
  
The physical half-life of the radionuclide should be long enough to allow for 
radiosynthesis preparation and be compatible with the pharmacokinetics of tumor localization.
23
 
The decay pathway of the alpha emitter should be carefully analyzed.  Due to the conservation of 
energy and linear momentum a daughter nuclide which subsequently decays by alpha emission 
could  detach from the radioimmunoconjugate, see for example.
24
 These free products could 
travel away and deposit dose to healthy tissue. A decay chain that is long and complicated, 
having many different decay types could also present an issue dosimetrically especially if the 
daughter products are metabolized differently than the parent.  A possible way to overcome this 
issue is to use 
225
Ac as an in vivo generator in which the delivery system is designed to be 
internalized into the target cell where the toxic daughter elements may detach from the targeting 
vector but remain trapped in the cell.
25
  
Another important nuclear characteristic is having a large number of alpha emissions per 
decay. The radiotoxicity associated with having multiple emissions could be high enough to kill 
a tumor cell in a single decay. An accompanying gamma photon emission with energy suitable 
for in vivo imaging is also beneficial to assist with pharmacokinetic and dosimetric evaluation.
23
 
Another important element for radionuclide selection is availability. Alpha emitters are 
produced either in cyclotron bombardment or by reactor irradiations, incorporated into a 
generator, and eluted from a parental source. Obtaining radionuclides in pure form with high 
specific activity and large quantities is essential for adequate therapeutic evaluation. High 
specific activity is important to avoid receptor saturation by the unlabeled targeting agent.
26
 If 
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membrane antigenic density is low, insufficient binding to tumor cells will occur.
26
 
Transportation of these radionuclides safely and economically is also a key issue in selection. 
While there are over 100 alpha emitting radionuclides, only several have been 
investigated in preclinical and clinical studies. This is mostly due to radionuclides lacking 
nuclear properties, the absence of viable chemistry, complicated decay chains, and production 
and economic issues.
27
 Therefore radionuclides meeting the criteria for therapeutic use have been 
limited to 
225
Ac, 
212
Bi, 
213
Bi, 
211
At, 
212
Pb, 
223
Ra, and 
227
Th. The physical characteristics of these 
isotopes can be seen in Table 1. 
 
Table 1. Physical characteristics of alpha emitting radioisotopes investigated for clinical use. 
Isotope Half-Life 
Max Energy 
(MeV) 
Emissions Per 
Decay 
225
Ac 10.1 d 5.83 4 α, 2β- 
211
At
 
7.2 h 5.87 1 α, 1 EC 
212
Bi 1.01 h 6.09 1 α, 1β- 
213
Bi 45.6 min 5.87 1 α, 2β- 
212
Pb 10.6 h 6.09 1 α, 2β- 
223
Ra 11.4 d 5.87 4 α, 2β- 
227
Th 18.7 d 6.04 5 α, 2β- 
 
The first alpha emitter to be used in human clinical trials for therapy was 
213
Bi in 1997, 
when it was labeled to the anti-leukemia antibody HuM195.
28
 
213
Bi is available through 
generator based 
225
Ac and decays with a 45.6 min half-life by emission of 1 alpha (8.37MeV) 
and 2 betas. The generator is produced at Oak Ridge National Laboratory in the US and at the 
Institute for Transuranium Elements in Karlsruhe Europe. In the decay of 
213
Bi, there is an 
emission of a 440keV isomeric gamma which is beneficial for imaging studies. 
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211
At decays with a half-life of 7.2 h and emits 2 alphas through a split decay pathway 
with energies of 5.87 and 7.45MeV. One path is to 
207
Bi by alpha emission followed by electron 
capture to 
207
Pb and the other is by electron capture to 
211
Po followed by alpha emission to 
207
Pb. 
An advantage of this decay path is that 
211
Po emits 77-92keV characteristic x-rays which can be 
used for imaging.
27
 The main disadvantages are availability and purity. Conventionally the 
production of 
211
At requires an alpha particle cyclotron, which there are only a few worldwide, to 
produce the 
209
Bi(alpha,2n)
211
At reaction with minimal 
210
At contamination.
29
 Astatine has 
significant metallic characteristics that lead to complications in standard antibody labeling and 
results in rapid release of free 
211
At.
27,30,31
 To resolve this problem, approaches have been 
developed in several research groups based on small linker molecules that create an aryl carbon–
astatine bond involving an astatodemetallation reaction using tin, silicon, or mercury 
precursors.
32
 
225
Ac is a radiometal with a half-life of 10.1 days and produces six radionuclide 
daughters in the decay path to stable 
209
Bi. For each decay event of 
225
Ac, there are successively 
four alpha and two beta emissions with high energy (alpha 8.38MeV, beta 1.42MeV). In the 
decay of 
225
Ac and its daughters there are several isomeric gamma emissions with energy 
suitable for imaging studies. The relatively long half-life allows for a centralized production site 
that can ship 
225
Ac to users.
33
 The main method for generating 
225
Ac for clinical studies is 
through the decay of 
229
Th which originates from 
233
U. In the world there are the three main 
sources of 
229
Th: Oak Ridge National Laboratory (USA), The Institute of Physics and Power 
Engineering (Russia), and The Institute for Transuranium Elements (Germany). The quantities 
produced are not enough for global application of 
225
Ac. To keep up with the increasing demand 
for 
225
Ac for clinical applications, it has been found that large scale quantities can be produced 
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through high energy proton irradiation of 
232
Th.
34,35
 To address the shortage the US Department 
of  Energy formed a Tri-lab  collaboration of Los Alamos (LANL), Brookhaven (BNL) and Oak  
Ridge (ORNL) National Laboratories with the goal of developing an alternative route for 
production of Ac.
36
  Another limitation for this radionuclide has been with the radiochemical 
stability of the attachment to immunoconjugate.  McDevitt et al.
25
 state that instability of these 
attachments is due to the high classical recoil energy (100-200keV) of the daughter product 
which breaks the molecular bonds of the chelator.  Significant advances have been made in 
developing chelators that form thermodynamically stable and kinetically inert complexes with 
225
Ac.  Khabibullin et al., recently calculated the chelation stability of 
225
Ac and daughters in the 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator.
37
  
As one potentially abundant starting material, 
212
Bi (1.01 h half-life) can be obtained 
from 
228
Th and decays via a branched pathway to 
208Tl (36% α) and 212Po (64% β), then both 
decay to stable 
208
Pb.
23
 However, 
212
Bi has several disadvantages that potentially limit its use. 
First, its short half-life can be problematic if the production and shipping processes are lengthy. 
This issue can be solved by using 
224
Ra as a generator to locally produce 
212
Bi. Another 
complication is the high energy gamma emission (2.6 MeV) which requires a considerable 
amount of shielding to minimize exposure. This along with the short half-life makes shipping 
difficult, resulting in an availability problem.  
 
223
Ra is found naturally in trace amounts following the decay of 
235
U, but it is mainly 
produced artificially by the decay of 
227
Th (T1/2 = 18.7 days), which is produced from 
227
Ac (T1/2 
= 21.77 years).  Since 
227
Ac is found only in traces in uranium and thorium ores, it is mainly 
synthesized by 
226
Ra (T1/2=1600 years) irradiation in a nuclear reactor.
38
  
223
Ra has a half-life of 
11.4 days and emits 4 alpha particles, 2 beta particles and gamma rays on the path to stable 
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207
Pb.
24
  While the emission of 4 alpha particles is advantageous for tumor toxicity, 
219
Rn in 
gaseous form is also emitted which can redistribute in the body and dose non-targeted cells.   
The major challenge using 
223
Ra is finding a suitable ligand for in vivo sequestration of 
radium. 
223
Ra has cationic charge similar to Ca
++
 and because of this it is readily taken into bone.  
Because of this characteristic,
223
Ra-dichlorde (Xofigo®) has demonstrated significant efficacy in 
the palliative treatment of bone metastases in castration resistant prostate cancer and has FDA 
approval for use in this application.
24
 However, this same property raises concerns about toxicity 
to normal bone if used for targeting cancer cells not associated with bone.  
227
Th can be produced continuously from 
227
Ac and decays with a half-life of 18.7 days to 
223
Ra
39
. The long half-life is beneficial for radiolabeling and targeting. 
227
Th also decays with 
accompanying gamma emissions of 236keV and 50keV which can be used for imaging but are 
low enough to avoid the need for patient shielding. 
212
Pb has a 10.6 h half -life and is produced either from the decay chain of 
228
Th or by the 
224
Ra generator.
29
 Because of its long half-life and the fact that 
212Pb is a β emitter that decays to 
212
Bi, one approach has been to use this radionuclide as an in vivo generator to compensate for 
the short half-life of 
212
Bi.
40 212
Pb can deliver over ten times the dose per unit of administered 
activity compared to 
212
Bi or 
213
Bi.
41
 The major issue with 
212
Pb is the electron capture and auger 
electron emissions which can cause significant recoil of the 
212
Bi daughter.
42
 The free 
212
Pb has 
been shown to cause severe bone marrow toxicity 
43
 while the free Bi has shown to cause kidney 
toxicity. By co-injecting DTPA or EDTA chelating agents, rapid release of free 
212
Bi can be 
achieved.
44
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2.3 Internal Radiation Dosimetry 
Dosimetry provides a means for evaluating the efficacy of a radiation therapy modality.
4
 
Because the goal is to deliver high dose to tumor cells with minimal dose to normal tissues, it is 
of great importance to quantify accurately where, when, and how dose is being deposited. The 
absorbed dose assessment involves the calculation of the total energy per unit mass of the 
volume of interest.
45
 These volumes can be whole organs, tissue subregions, voxelized tissue 
structures, or individual cellular compartments.
46
  Internal radiation dosimetry requires the 
knowledge the radionuclide’s physical properties (i.e. type of particles, emission energies, 
abundances, half-lives) and the measurements of biological properties (i.e. uptake, clearance, and 
tissue masses). Internal dosimetry can be divided into two categories: fixed-geometry and 3D 
image based dosimetry. 
The conventional method of internal dosimetry was developed by the Medical Internal 
Radiation Dose Committee (MIRD) in the 1960’s. The MIRD method falls into the fixed 
geometry category. In this method, the dose calculation is dependent on the amount of activity as 
a function of time in a source organ, the energy emitted per disintegration and the fraction of 
emitted energy absorbed by a target organ.
47
 The fraction of energy absorbed from a source 
organ to a target organ for a given radionuclide is derived from a fixed geometry using a 
standard anatomical model. 
The fundamental equation for calculating absorbed dose using the MIRD schema is given in 
Equation 1. 
                                                   𝐷𝑥(𝑟𝑇 , 𝑇𝐷) = ?̃?(𝑟𝑆, 𝑇𝐷)
∑ ∆𝑖
𝑥
𝑖 𝜑(𝑟𝑇←𝑟𝑆;𝐸𝑖
𝑥)
𝑀(𝑟𝑇)
                                            (1) 
where ?̃?(𝑟𝑆, 𝑇𝐷) is the total number of nuclear transitions in the target region, ∆𝑖
𝑥 is the mean 
energy emitted per disintegration for the i
th
 emission of type x, 𝜑(𝑟𝑇 ← 𝑟𝑆; 𝐸𝑖
𝑥) is the fraction of 
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energy emitted per nuclear transition in the source region that is absorbed in the target region by 
the i
th
 emission of type x that is emitted with initial energy E, and 𝑀(𝑟𝑇) is the mass of the target 
region. ?̃?(𝑟𝑆, 𝑇𝐷), known as the cumulated activity, describes the kinetic portion of the dose and 
depends on the spatial and temporal distribution of the radionuclide. Serial activity 
measurements are taken over time post-administration and a time activity curve (TAC) is 
generated. The TAC is then fitted with a kinetic compartmental model and integrated over time 
to determine the total number of disintegrations in the source organ: 
                                                         ?̃?(𝑟𝑆, 𝑇𝐷) = ∫ 𝐴𝑠(𝑡)𝑑𝑡
𝑇𝐷
0
                                                      (2) 
The mean energy emitted per emission  ∆𝑖 is a physical property of the radionuclide and 
can be obtained from nuclear decay tables. The absorbed fraction for each decay type, 𝜑, is 
dependent on the reference phantom fixed geometry and obtained through Monte Carlo 
calculations. One can define an “S” value as: 
                                                          𝑆 =
∑ ∆𝑖
𝑥
𝑖 𝜑(𝑟𝑇←𝑟𝑆;𝐸𝑖
𝑥)
𝑀(𝑟𝑇)
                                                             (3) 
Reducing Equation 1 to: 
                                                           𝐷𝑥(𝑟𝑇 , 𝑇𝐷) = ∑ ?̃?(𝑟𝑆, 𝑇𝐷)  × 𝑆𝑟𝑠                                                (4) 
The S value is pre-calculated and tabulated from the fixed geometry and tabulated for each 
particular radionuclide.  
The value of the MIRD schema is its simplicity in that the physical aspects of the dose 
calculation are separated and all that needs to be obtained experimentally is the temporal kinetic 
information. The disadvantages of this method are in the broad assumptions that are made. This 
conventional method for the calculation of mean absorbed dose assumes uniform activity within 
the source volumes as well as assuming that the result will be predictive of biological effects. 
The spatial distribution of activity cannot be determined. The anatomical model is based on a 
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very primitive mathematical geometry consisting uniform density shapes. The most extensive 
software that has adapted the MIRD S factors is OLINDA/EXM which has calculated internal 
dose for over 200 radionuclides, including alpha emitters, in 10 different phantoms.
48
 The 
predetermined S values from these phantoms are unrealistic for human application. As a result of 
these assumptions it has been estimated that errors range from 30-100%.
49
 In therapeutic 
applications, where tumor control probability and normal tissue toxicity are of utmost 
importance, this standardized fixed geometry is unacceptable. In radionuclide therapy, especially 
alpha therapy, nonuniform activity distributions arise over temporal and spatial dimensions. 
Using the mean absorbed dose will under- or- over estimate subregions in the volume of interest. 
The outcome of a therapy is then limited by the normal tissue toxicity.
50
 
With the development of high quality 3-dimensional imaging capabilities and increasing 
computational power, patient specific internal dosimetry has become possible. Using 3D 
computed tomography (CT) images, a phantom specific to the patient’s anatomy can be 
generated. Accurate organ volumes, location and densities are obtained through CT imaging. 
These voxelized volumes are segmented into regions of interest (ROI’s) to define source and 
target regions. Functional imaging such as single photon computed tomography (SPECT) or 
positron emission tomography (PET) is then used to obtain spatial and temporal biodistribution, 
at the voxel level, in the ROI’s. The SPECT/CT images are registered together and integrated 
voxel by voxel over time to obtain the 3D time integrated activity. A Monte Carlo package is 
then employed to model particle transport and energy deposition in each voxel.  
Three methods of 3D voxel-based dosimetry using Monte Carlo can be used: (1) the 
voxel S value method, (2) the point dose kernel convolution method, and (3) full direct Monte 
Carlo calculation 
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The fastest is the voxel S value method. This method extends on the original MIRD 
schema by developing voxelized phantoms to better match standard human anatomy. For 
example, Christy and Eckerman developed phantoms that represented a male, a female, and 
children.
51
 Later, as computational power increased, voxelized phantoms like VoxelMan were 
created based off of 3D imaging.
52
 MIRD Pamphlet No. 17 describes a method to extend the S 
value formalism to the voxel level to account for nonuniform distributions of activity.
53
 While 
accuracy is improved, the voxel S value method is still a model based approach to dosimetry. 
In the point dose kernel convolution method, Monte Carlo is used to generate 
radionuclide specific absorbed dose per decay maps at radial distances from an isotropic point 
source in a homogeneous medium. The patient specific activity distribution obtained from 
SPECT imaging is then convolved with the dose kernel to obtain a 3D dose distribution. The 
major disadvantage of this method is that since the dose kernels are obtained in homogeneous 
media, tissue heterogeneity is not modeled.  
The most accurate method for calculating 3D internal absorbed dose at the voxel level is 
direct Monte Carlo calculation. With full Monte Carlo simulation, all emission types can be 
simulated, tracked, and tallied to generate 3D dose distributions specific to the patient’s anatomy 
accounting for tissue heterogeneity. The patient’s CT dataset is converted into a voxelized 
phantom. Each voxel is defined to have a specific elemental composition and density creating an 
attenuation map. The patient’s SPECT provides the voxelized activity distribution map for the 
Monte Carlo source definition. Full Monte Carlo simulations are performed and energy 
deposition is tallied in every voxel within the patient derived phantom. Several software 
packages are available for 3D patient specific dosimetry including MCID 
54
, OEDIPE 
55
, and 
SCMS 
56 
which are based on MCNP, 3D-RD 
57
 and DOSIMG 
58
 which are based on EGS 
59
, 
 21 
RAYDOSE 
60
 and RAPID 
61
 which are based on GEANT4 
62
, and DPM 
63
 which is not a public 
domain code. Both MCNP and GEANT4 can simulate alpha particles while EGS can only 
transport photons and electrons. While direct Monte Carlo methods are the most accurate means 
to perform 3D image based internal dosimetry, their use in the clinic has been limited due to 
complexity and expensive computational requirements. 
While many radionuclides in radiopharmaceutical therapy have accompanying photon 
emissions, the energies and abundances are not large enough for practical 3D biodistribution 
studies using SPECT or PET. To overcome this obstacle, companion imaging agents have been 
developed. This theranostic approach involves developing a SPECT or PET tracer compound 
that will have similar biodistribution and pharmacokinetics as the therapeutic. For optimized 
treatment planning, the imaging agent is administered, the 3D accumulated activity distribution 
is obtained, and one of the above Monte Carlo approaches is employed to calculate what the 
absorbed dose will be in organs of interest following administration of the therapeutic agent. 
This approach has been used for pretreatment dosimetric analysis for many 
radiopharmaceuticals. Examples of using the theranostic approach include using 
123
I/
 131
I
 
-
metaiodobenzylguanidine (mIBG) in neuroblastomas, pheochromocytomas, and 
paragangliomas
64
, 
99m
Tc/
 188
Re-hydroxyethylidene diphosphate (HEDP) for osteoblastic bone 
metastases
65
, 
68
Ga/
177
Lu-DOTA-TATE for peptide receptor radionuclide therapy of metastatic 
neuroendocrine neaoplasia
66
, 
18
F/
131
I-F-ICF15002 for metastatic melanoma
67
, and 
111
In/
90
Y-
ibritumomab tiuxetan for B-cell non-Hodgkin’s lymphoma68. For image based dosimetry of the 
223
Ra-dichloide alpha emitting radiopharmaceutical, 
99m
Tc-methyl diphosphonate has shown to 
be a suitable companion imaging agent in the treatment of treatment of bone metastases
69
. The 
68
Ga/
225
Ac-Prostate-specific membrane antigen-617 (PSMA-617) 
70
 and the 
203
Pb/
212
Pb-DOTA-
 22 
MC1L
71
  pairs have also been used in dose calculations for the targeted alpha therapy of 
metastatic castration resistant prostate cancer and metastatic melanoma respectively. 
The use of companion imaging agents for dose calculations improves on conventional 
methods. However, in most cases, the kinetic data obtained from the images are input into 
OLINDA and only mean organ doses are reported. For optimized treatment planning, the 
dosimetry calculations need to be performed at the voxel level. In this work I will expand on the 
conventional method of internal dose calculation used by OLINDA by developing a 
methodology using a companion imaging agent to calculate absorbed dose at the voxel level for 
our targeted alpha therapy. 
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CHAPTER THREE: 
A MONTE CARLO METHOD FOR DETERMINING THE RESPONSE 
RELATIONSHIP BETWEEN TWO COMMONLY USED DETECTORS TO 
INDIRECTLY MEASURE ALPHA RADIATION 
 
Note to Reader 
This research was originally published in Molecules. A Monte Carlo Method for Determining the 
Response Relationship between Two Commonly Used Detectors to Indirectly Measure Alpha 
Particle Radiation Activity. Christopher J. Tichacek, Mikalai Budzevich, Thaddeus J. Wadas, 
David L. Morse, Eduardo G. Moros. Molecules 2019, 24(18), 3397. 
 © 2019 by the authors. Licensee MDPI, Basel, Switzerland. 
 
3.1 Introduction 
The use of targeted ligands to deliver alpha particles directly to cancer cells has become a 
promising strategy to treat tumors.
70,72-74 
This is because of their short path length of 40–80 µm 
and high linear energy transfer (LET~100 keV/µm).
75
 These two properties make alpha particles 
highly cytotoxic to targeted cells, with little damage to surrounding normal cells. 
Owing to the large amount of energy deposited by alpha particles, it is important to quantify 
the radioactivity of the targeted radiopharmaceutical initially injected and its subsequent 
biodistribution, pharmacokinetics, and radiation dose deposited in various tissues. As a result of 
its short path length, the direct measurement of alpha particles’ activity in tissues is not possible 
in most, if not all, preclinical scenarios. If a parent metastable radioisotope also emits gamma 
rays, indirect methods of detection such as gamma spectroscopy can be used to estimate activity 
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using scintillation detectors and well-type ion chambers that are commonly available in research 
laboratories and nuclear medicine clinics. 
Actinium-225 (
225
Ac) was chosen as the radionuclide for alpha-particle therapy (TAT) 
targeted to the melanocortin 1 receptor for treatment of metastatic uveal melanoma
76
, the 
prostate-specific membrane antigen (PSMA) for metastatic prostate cancer
72
, and CD33 for acute 
myeloid leukemia.
77
 Clinical studies have been carried out for the PSMA and CD33 TATs and 
others in pre-clinical development will soon go to clinical trials.
76
  
225
Ac has a 10-day half-life and decays via six daughter radionuclides resulting in a net of 
four alpha particles per Actinium disintegration (Figure 2).
20,78
 
225
Ac and two of its daughters, 
221
Fr and 
213
Bi, also decay with accompanying isomeric gamma photons. Using gamma detection 
systems, such as ion chambers or scintillation detectors, it is possible to indirectly determine the 
alpha activity by gamma ray abundance per decay conversions. 
 
Figure 2. Decay chain of Actinium-225 (
225
Ac).
79
 
 
In the clinic, ion chambers are readily available and their use is the standard of practice for 
checking activities for diagnostic and therapeutic agents. An ion chamber reading does not 
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discriminate the collected charge between the parent and daughter radionuclides because it does 
not provide energy identification. In these situations, gamma spectroscopy using scintillation or 
semiconductor detectors, such as a sodium iodide doped with thallium scintillation detector 
[NaI(Tl)] or a high purity germanium (HPGe) detector, can be used. With this approach, it is 
possible to determine the activity of each gamma emitting daughter, which gives more 
information on how the decay species behave. 
While HPGe seems to be the attractive option owing to its superior energy resolution, its 
performance suffers as a result of its low detection efficiency, cost, and requirement of 
sophisticated cooling systems. Despite the advantages of the NaI(Tl), dead time losses at higher 
activities and poor energy resolution may also provide incorrect activity measurements, leading 
to underestimation or overestimation of radiation dose.
80
 
In pre-clinical and clinical biodistribution studies, activity measurements of collected blood 
and tissues are used to calculate pharmacokinetics and radiation dosimetry. Therefore, accurate 
measurements for 
225
Ac and daughters are needed. Hence, scintillation detector measurements 
are needed to generate these spectra. Alpha radiation dosimetry is performed using the methods 
recommended by the Committee on Medical Internal Radiation Dose.
4,46
 It is essential that these 
measurements are accurate because the dosimetry estimates are then extrapolated to human 
estimations and, therefore, serve as the fundamental basis for all patient safety measures. 
Scintillation detectors are calibrated by analyzing three aspects of the detector: energy, 
resolution, and efficiency.
81
 Once the detector is fully calibrated, it can be used to perform 
gamma spectroscopic measurements in order to determine the activity of radioactive samples.
82-
87
 Ion chambers are calibrated by measuring a sample of the radiopharmaceutical in question 
with known activity, correcting for decay, and applying a calibration factor. The American 
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National Standards Institute (ANSI) recommends that the applied calibration factor adjusts the 
measurement to within ±10% of the known activity.
88
 Although reference standards have been 
developed for isotopes used in internal radiotherapy, for example, 
177
Lu 
89
 
225
Ac standards are 
currently under development by NIST and are not yet available. For this study, 
225
Ac provided 
by Oak Ridge National Lab was used as a cross-reference source. 
While there are evident limitations in making clinical predictions when translating a 
radiopharmaceutical from mice to humans, it is important to minimize these limitations that are 
the result of instrumentation. Herein, a threshold is identified above which the scintillation 
detector cannot accurately measure the activities of 
225
Ac and daughters. An activity response 
relationship between the ion chamber and scintillation detector measurements is reported and 
used in a method to improve activity determination above the threshold by correcting 
scintillation detector measurements via Monte Carlo simulations. These corrections improve the 
dosimetry of pre-clinical work and ultimately facilitate the translation of the new 
radiopharmaceutical to the human clinic.  
 
3.2 Materials and Methods 
3.2.1 Mathematical Model 
The 
225
Ac decay chain can be characterized by a system of ordinary differential equations that 
describe the activities and abundances of each species as a function of time (Figure 3).
90
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Figure 3. System of equations describing the decay of 
225
Ac to the very long-lived 
209
Bi.
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In Figure 3, 𝑁𝑥 and 𝜆𝑥 denote the number of atoms of radionuclide and the decay constant of 
radionuclide X, respectively. These equations were simultaneously solved in Mathematica with the 
initial (time zero) 
225
Ac activity set to 3.7 x 10
4
 kBq and all daughters’ activities set to 0 kBq to 
determine the times at which daughter products reach equilibrium with the parent.  
 
3.2.2 Monte Carlo Model 
The Monte Carlo N-Particle version 6.1 (MCNP6.1) package was used to simulate the pulse 
height gamma distribution from 
225
Ac.
91 A computational model of the 2” × 2” NaI(Tl) 4π detector 
was built using the material compositions and dimensions given in the manufacturer’s manual, as 
illustrated in Figure 4.
92
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Figure 4. Geometry of the Monte Carlo model wipe test scintillator detector. Image generated 
using the Visual Editor software for MCNP. 2: NaI; 3: MgO; 4: Al; 6: polyethylene; 7: air; 8: H20 
with 
225
Ac, 
221
Fr, 
213
Bi source distributions.
79
 
 
A standard 5 mL polyethylene test tube filled with 1 mL of water was placed in the well of the 
detector. The source was defined to be uniformly distributed in the 1 mL water volume. All 75 
photon emissions from 
225
Ac, 
221
Fr, and 
213
Bi were defined by energy and abundance.
78
 The 
photomultiplier tube was modeled as a 30 mm diameter aluminum cylinder to account for 
backscatter.
93
 
Photon transport was conducted using the mcplib84 photoatomic data library and detailed 
photon physics interactions.
78
 These include Thomson scattering, Compton scattering, and 
photoelectric absorption with the creation of fluorescence photons or Auger electrons. Full photon 
and electron simulations were performed and spectra were compared to those obtained from only 
photon transport. Photon and electron cell importances were set to 1 for all cells in the geometry. A 
mean percent difference of less than 1% between photon/electron transport and photon only 
transport was observed in benchmark generated spectra of 
137
Cs. There were also less than 1% 
differences in the Compton edge and Compton regions. Therefore, the computationally expensive 
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tracking of electrons was omitted in subsequent simulations and electron cell importances were set 
to 0. In this case, the electrons generated are assumed to deposit their energy locally. Any electron 
induced bremsstrahlung photons produced are accounted for in the thick-target bremsstrahlung 
model.
94
 This model skips the electron tracking step and transports the generated photon in the 
direction of the parent electron. 
The pulse height distribution tally (F8) was used to calculate the deposited energy in the 
NaI(Tl) crystal. This tally accumulates the kinetic energy lost by local photon-induced secondary 
electrons, per history, in a specified volume. The tally was divided into 64 bins, each with a 12.5 
keV width to match the energy resolution of the detector. To relate the simulated response to 
activity, values for the number of gamma emissions per disintegration for each isotope, scaled by 
the activity, were placed on the source probability card in the source definition. The resulting 
tallies were then multiplied by the sum of these values, the live acquisition time, and an activity 
conversion factor containing photon abundance per decay. For each simulation, 2 x 10
8
 histories 
were run to achieve less than 1% error under each photopeak. 
MCNP6.1 models an ideal detector and thus does not take into account the Gaussian shape of 
experimental NaI(Tl) energy resolution resulting from intrinsic light collection inefficiency, 
statistical fluctuation in charge multiplication in the photomultiplier tube, and electronic noise.
95
 
To account for the statistical variance of physical spectra, a Gaussian energy broadening function 
(MCNP6.1 FT8 GEB) was applied to the simulated pulse height distribution. The GEB function 
was obtained experimentally from measurements of the detector’s specific full width at half 
maximum (FWHM) from a set of isotopes of differing energies. Spectra from five isotopes were 
measured and the FWHM of each peak was calculated. The isotopes used and their physical 
characteristics are listed in Table 2. 
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Table 2. Physical characteristics of the radioactive sources used for NaI(Tl) detector energy 
response measurements.
78,79
 
Source Half-Life Energy (keV) 
129
I 1.6
7
 yr 39.5 
241
Am 432.6 yr 59.5 
57
Co 271.7 d 122.0 
68
Ga 67.7 m 511.0 
137
Cs 30.1 yr 661.6 
 
A curve of FWHM as a function of energy was fit with the following nonlinear function 
shown in Equation 5
91
: 
𝐹𝑊𝐻𝑀 = 𝑎 + 𝑏√𝐸 + 𝑐𝐸2, (5) 
where E is the incident energy of the incident photon in keV; and a, b, and c are parameters that 
were determined by least squares fitting and input in the FT8 command. 
 
3.2.3 Monte Carlo Simulations 
There are no standard NIST-traceable calibration sources for 
225
Ac to validate the detector 
model. Instead, the spectrum of a NIST-traceable 155.4 kBq 
137
Cs (662 keV photopeak) source 
was measured in the NaI(Tl) detector and compared to a simulated spectrum of the same activity 
for validation. 
After the model was validated, a high definition version of the F8 pulse height tally (1 keV bin 
width) was simulated with only 
225
Ac defined as the source. This was followed by separate high 
definition simulations of 
221
Fr and 
213
Bi. These simulations were done to see what radiations 
contribute to each peak, which are masked by the poor energy resolution of the NaI(Tl) detector.  
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3.2.4 Experimental Measurements 
The 
225
Ac used in this work was obtained from Oak Ridge National Laboratory (ORNL). The 
Atomlab
TM
 Wipe Test Counter (Biodex Medical Systems, Inc., Shirley, New York, USA) was 
used to perform gamma spectroscopy measurements with 
225
Ac. The wipe test counter is a 2” × 2” 
NaI(Tl) well-type scintillation detector with 1.2 cm of lead shielding. The multichannel analyzer 
associated with the wipe test NaI(Tl) detector has 64 12.5 keV channels ranging from 0 to 800 
keV. Spectra obtained with the NaI(Tl) detector for 30 s acquisition time and full energy window 
to include gamma counts from 
225
Ac, with composite peak at 99.8 keV, and from its two gamma-
emitting daughters, 
221
Fr (T1/2 = 4.9 min) with a peak at 218.1 keV and 
213
Bi (T1/2 = 46 min) with a 
peak at 440.5 keV. Background spectrum measurements were performed and subtracted from all 
obtained 
225
Ac spectra. The net background readings for the NaI(Tl) detector were in the range of 
100 to 200 net counts per minute. The net counts for an 
225
Ac sample of 45 kBq activity was 
444,000 per minute. 
Dead time measurements and calculations were performed according to the two-source 
method.
80
 Two different sources of 
22
Na with different activities were each measured individually 
and then in combination. 
In-house software was developed using MATLAB to calculate the net number of gamma 
counts, N, by fitting each peak with a Gaussian fit and integrating. Alpha particle activity for each 
species was calculated using factors for gamma abundance (Y) per alpha decay: 
225
Ac (1%), 
221
Fr 
(11.4%), 
213
Bi (25.9%).
78
 
The detector efficiency, ε, and energy calibration for the NaI(Tl) detector were determined by 
performing measurements of NIST-traceable 
137
Cs, 
133
Ba, and 
57
Co sources. These radionuclides 
 32 
have numerous photopeaks covering the gamma energy spectrum of 
225
Ac. The activity is then 
given by the following Equation 6: 
𝐴 =  
𝑁
𝑡 ∗ 𝜀 ∗ 𝑌
, (6) 
where t is live time. The activity of 
225
Ac determined using this approach was compared to a decay 
corrected sample of known activity from ORNL. A factor of 0.082 was applied to Equation 2 to 
obtain 
225
Ac activity values to within 5% of the ORNL specified 
225
Ac activity. The uncertainty in 
the NaI(Tl)-determined activity was calculated by propagating individual uncertainties in the net 
number of counts and the efficiency measurements, as is typically done in nuclear counting 
measurements.  
The Atomlab
TM
 500 Dose Calibrator is a well-type pressured ion chamber filled with argon 
gas that is commonly used in the clinic. This instrument was calibrated for energy and efficiency 
with the following NIST-traceable sources: 
137
Cs (6.63 MBq), 
57
Co (39.26 MBq), and 
133
Ba (5.71 
MBq) by the vendor. Lower activity NIST-traceable sources provided by Eckert & Ziegler were 
also used: 
137
Cs with 158.73 kBq and 
57
Co with 391.09 kBq activities. No significant variation in 
the calibration coefficient as a function of photon energy was observed. An ion chamber linearity 
test was performed with 
18
F in the activity range of 1.2 GBq to 266.0 kBq and a variance of 1.4% 
was observed. The dial number was set at 38.2 for 
225
Ac, as indicated by the vendor and confirmed 
by our comparison with two decay corrected samples of different activities obtained from Oak 
Ridge. Measurements of these samples in the ion chamber agreed with the Oak Ridge 
measurements to within 7%. In order to determine the relationship between this ion chamber and 
the NaI(Tl) detector, six different activities of 
225
Ac samples were measured using the ion 
chamber: 70.3 ± 7.0, 144.3 ± 14.4, 222.0 ± 22.2, 299.7 ± 30.0, 370.0 ± 37.0, and 447.7 ± 44.7 kBq. 
Each sample was measured and placed in the NaI(Tl) detector, and a spectrum was obtained and 
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compared. Using the activity reading from the ion chamber as the initial parent–daughter 
equilibrium activity input for the Monte Carlo model, simulated spectra were calculated and 
compared to the measured spectra from the NaI(Tl) detector. Mean absolute percent differences at 
analogous bins between the experimental and simulated spectra were calculated. Using the ion 
chamber measured activity as input to the Monte Carlo simulations underestimated the readings 
from the NaI(Tl), so several successive runs were completed using different activities as input in 
symmetrical range around the initial point in order to match the spectra. The percent differences 
were plotted against input activity and fitted with a linear model. The x-intercept was found in 
order to determine the minimum mean percent difference between the measured and simulated 
spectra. This process was repeated for each sample and an activity response function relationship 
was determined between the ion chamber and the NaI(Tl) detector. The uncertainty in the activity 
relationship determined using this methodology was analyzed by adding the uncertainties in the 
NaI(Tl) measurements, 𝜎𝑁𝑎𝐼
2 ; the ion chamber measurements, 𝜎𝐼𝐶
2 ; and the Monte Carlo 
calculations, 𝜎𝑀𝐶
2 , in quadrature (Equation 7): 
𝜎𝐴 = √𝜎𝑁𝑎𝐼
2 + 𝜎𝐼𝐶
2 + 𝜎𝑀𝐶
2 . (7) 
 
3.3 Results 
The system of ordinary differential equations describing the 
225
Ac decay chain was solved to 
determine the daughters’ activities as a function of time; these results are plotted in Figure 8 for 
225
Ac, 
221
Fr, and 
213
Bi. For an initial activity of 3.7 × 10
4
 kBq of 
225
Ac, 
221
Fr reaches secular 
equilibrium with 
225
Ac in 55 minutes, while 
213
Bi takes 380 minutes. Therefore, after 380 
minutes (6.37 h), the parent and all daughter nuclides are in secular equilibrium. 
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Figure 5. Solutions to system of decay ordinary differential equations of for an initial activity of 
3.7 × 10
4
 kBq of 
225
Ac.
79
 
 
To account for the statistical variance of physical spectra, a Gaussian energy broadening 
function was integrated with the ideal Monte Carlo simulation model. The parameters of this 
function were determined by nonlinear fitting of the measured FWHM versus energy. These 
parameters were determined to be a = 0.005616, b = 0.0521, and c = 2.027 with an R-squared 
value of 0.9984. This allowed the benchmark validation of the Monte Carlo model using the 
137
Cs standard source (Figure 6). Simulating 155.4 kBq, the known source activity, showed a 
1.02 mean percent difference at analogous bins between measured and simulated spectra.  
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Figure 6. Comparison of measured and simulated spectra of 
137
Cs.
79
 
 
The measured NaI(Tl) gamma spectrum and Gaussian peak fitting of 
225
Ac and its daughters 
can be seen in Figure 10. The two source method was used to determine the dead time of the 
scintillation detector to characterize the saturation of the signal with increasing activity. The 
value was determined to be 4.6 × 10
−5
 s
-1
. The dead time value was incorporated into the gamma 
spectrum fitting method that was used to determine the scintillation detector activities of 
225
Ac, 
221
Fr, and 
213
Bi, and these values were compared to the ion chamber measurements (Table 3). All 
samples were in secular equilibrium during measurement, as shown in Figure 8. The ion chamber 
manufacturer error is reported as 3%. Measurements using NIST-traceable sources within the 
activity range of 5.705 to 39.257 MBq had 3% uncertainties. However, when measuring NIST-
traceable sources at the lower activities of 158.73 and 391.09 kBq, the uncertainties were 9.7% 
and 9.6%, respectively. 
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Figure 7. NaI(Tl) measured gamma spectrum with Gaussian fitting.
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Table 3. Ion chamber and NaI(Tl) measured activities. Single measurements were taken in each 
detector. Notice that as the ion chamber readings increase, the discrepancies with the NaI(Tl) 
increase. All values in kBq. Note that the uncertainties in the ion chamber readings are expressed 
as 10% in accordance with the calibration measurements in the activity range (above). The 
NaI(Tl) uncertainties are expressed as the propagation of uncertainties in all steps of the 
calculation. The difference between the ion chamber readings and the NaI(Tl) determined 
activity for 
225
Ac are indicated in the last column to the right.
79
 
Ion Chamber Reading 
NaI(Tl) Determined Activities  
225
Ac 
221
Fr 
213
Bi 
225
Ac 
Percent 
Difference 
70.3 ± 7.0 57.35 ± 7.57 66.97 ± 8.18 63.64 ± 7.98 20.23 
144.3 ± 14.4 96.20 ± 9.81 115.07 ± 10.73 111.74 ± 10.57 40.00 
222.0 ± 22.2 124.69 ± 11.17 152.81 ± 12.36 143.93 ± 12.00 56.14 
299.7 ± 30.0 140.23 ± 11.84 177.97 ± 13.34 165.39 ± 12.86 72.50 
370.0 ± 37.0 152.07 ± 12.33 198.32 ± 14.08 182.41 ± 13.51 83.49 
447.7 ± 44.7 140.23 ± 11.84 211.64 ± 14.55 187.59 ± 13.70 104.59 
 
The spectra acquired by the scintillation detector (Figure 8) have overlapping multiple peaks 
that are further masked by the poor resolution of the detector. Monte Carlo simulations with 1 
keV resolution were run for the parent and gamma emitting daughter radioisotopes. As observed 
in Figure 5, 
225
Ac, 
221
Fr, and 
213
Bi all exhibit many peaks in the 90 to 200 keV range. Monte 
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Carlo simulations allowed for the accounting of contributions from each individual radioisotope 
to the overlapping gamma spectra. 
 
 
Figure 8. High definition Monte Carlo simulated gamma spectra of (A) 
225
Ac, (B) 
221
Fr, 
(C) 
213
Bi, and (D) all three superimposed.
79
 
 
 
Monte Carlo simulations were run using the bin width of the NaI(Tl) detector and ion 
chamber readings. The resulting spectra were compared to the corresponding scintillation 
detector spectra and it was observed that as the readings increased, the percent difference 
between the measured and simulated spectra increased. The percent differences ranged from 
19% at 70.3 kBq up to 156% at 447.7 kBq. This is illustrated in Figure 9. The readings that 
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minimized the mean percent differences were used as the equilibrium input activities in the 
Monte Carlo simulations. Figure 10 shows the matching of simulated spectra to measured spectra 
for all six of the samples of different quantities. This procedure was repeated for all ion chamber 
readings. Figure 11 shows the ion chamber reading and the simulated activity that matches to 
within 1% of the NaI(Tl) spectra for all of the samples. At low readings, the measured and 
simulated quantities agree reasonably well: 70.3 kBq measured in the ion chamber matched with 
62.9 kBq equilibrium Monte Carlo activity and 144.3 kBq measured in the ion chamber matched 
with 107.3 kBq Monte Carlo activity. For larger ion chamber readings, the matched response 
began to plateau. 
 
 
Figure 9. The mean percent difference between measured spectra and simulated spectra using the 
ion chamber reading measurement as input for the Monte Carlo model.
79
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Figure 10. Measured vs. simulated 
225
Ac spectra for (A) 70.3 kBq (0.17%), (B) 144.3 kBq 
(0.5%), (C) 222.0 kBq (0.19%), (D) 299.7 kBq (0.99%), (E) 370.0 kBq (0.11%), and (F) 447.7 
kBq (0.02%). The values in parentheses are the mean percent differences between the two 
spectra.
79
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Figure 11. Activity response relationship between ion chamber reading and Monte Carlo-NaI(Tl) 
corrected spectra activity.
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3.4 Discussion 
The purpose of this work is to develop a method to determine the activities of 
225
Ac and 
daughters in samples using standard clinical instruments. This is important for the determination 
of blood clearance pharmacokinetics and tissue biodistribution, both of which are used for 
radiation dosimetry calculations. In this work, an activity response relationship is determined 
between two radiation detectors commonly used for pre-clinical and clinical applications, a well-
type NaI(Tl) scintillation detector and an ion chamber, respectively, where 
225
Ac activities 
between the range of 70 to 450 kBq are not accurately measured by the scintillation detector. 
This relationship was used to inform Monte Carlo simulations that corrected scintillation detector 
measurements for accurate readings within this range. Although the error of the ion chamber 
measurements increased to ~10% within this activity range, compared with errors of 3% 
observed when measuring activities as low as 6 MBq, the error within this range for the 
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scintillation detector as compared with the benchmarked Monte Carlo simulations ranged from 
20% to 160% (Figure 9). 
Several preclinical studies have reported using a NaI(Tl) gamma counter to measure 
225
Ac 
injection and biodistribution activities.
25,96-99
 Ion chambers are commonly used in nuclear 
medicine departments to prepare radiopharmaceuticals for patient injection. Measuring the 
activity of radioisotopes with complicated decay pathways, such as in the case of 
225
Ac, the 
readings are not only the result of the parent’s activity, but also from the contributions from the 
daughters’ activities. From the solution of the system of decay equations, it was determined that 
225
Ac and its daughters reached secular equilibrium in less than seven hours. While the daughters 
emit alpha particles and/or beta particles, the ranges of these particles are not penetrative enough 
to enter the ion chamber. Therefore, the ion chamber reading is a result of the gamma rays 
emitted from 
225
Ac, 
221
Fr, and 
213
Bi. For example, a recent human 
225
Ac therapy study reported 
injection activities for 
225
Ac, but it was not clear if the reported values were from bulk 
measurements or if spectra were acquired and only 
225
Ac emissions were considered.
78
 
Several groups have built Monte Carlo models of NaI(Tl) detectors to simulate response 
functions based on standard benchmark simulations and measurements of 
137
Cs without 
description of further extensions of their models.
93,100-104 
Herein, this procedure was extended to 
include the detector response for 
225
Ac and its daughters. Implementation of the adjustment 
coefficients obtained by the nonlinear fitting into the Monte Carlo model adequately described 
the Gaussian spread of the detector pulses and was evident in benchmark testing. For all 
simulations, it was assumed that 
225
Ac, 
221
Fr, and 
213
Bi were in secular equilibrium and thus had 
equal activities. The high-definition Monte Carlo simulations showed that both 
221
Fr and 
213
Bi 
exhibit peaks in the energy range of 
225
Ac gamma pulse height distribution. Because of the 12.5 
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keV energy resolution of the NaI(Tl) detector, these peaks are summed to form a larger 
composite photopeak resulting in greater net counts, and thus over-calculated activities. 
Gamma spectroscopic measurements were performed using the NaI(Tl) scintillation 
detector. All samples were measured after the calculated time to reach secular equilibrium, but 
the resulting activities were not equal. Further, the sum of activities for all three species greatly 
overestimated the ion chamber readings. Although the activities determined for the three isotopes 
should theoretically be identical, discrepancies are the result of the low energy bin resolution of 
the detector and the dead time count saturation. Using the measured ion chamber readings as 
input to the Monte Carlo simulations (Figure 9) largely overestimated the measured NaI(Tl) 
spectrum. 
After minimizing the difference between each sample spectra and the Monte Carlo output, 
an activity response function relationship was determined for the two detectors (Figure 11). Both 
the Monte Carlo activity and the ion chamber reading represent the sum of the activities of 
225
Ac, 
221
Fr, and 
213
Bi. The plot shows a curve with a decreasing positive slope as the ion chamber 
measurements increased beyond 148 kBq. This is a result of the NaI(Tl) dead time losses. As the 
activity of a sample increases, more pulses are lost, leading to errors in counting. The 
discrepancy between the low energy measured and simulated peaks in Figure 10 is also a result 
of dead time effects. The ratio of simulated to measured peaks increases with increasing activity 
because the Monte Carlo model does not account for dead time. Further, the disagreement in the 
simulated and measured spectra in the low count region arises from the fact that the model 
represents an idealized detector and does not account for the metallic impurities of a real 
detector. 
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Standard NIST-traceable samples of 
225
Ac are currently unavailable, so 
225
Ac obtained from 
Oak Ridge was used as a surrogate calibration reference. These samples did not come with 
uncertainty estimations. As measurements using the recommended dial number agreed with the 
Oak Ridge surrogate reference samples to less than 10%, the readings of the ionization chamber 
were considered reliable for the study carried out in this work. The scintillation detector’s 
measured energy resolution and detection efficiency over the energy range of 
225
Ac gamma 
emissions (40-662 keV) agreed with other published studies and reports.
92,101,105,106 
Consequently, this detector was also considered to be calibrated in efficiency and energy for 
225
Ac analysis. The calibration sources used were all less than 185 kBq. When calibrating the ion 
chamber with sources with activity above 5.71 MBq, the error was less than 3%. When testing 
with sources in the lower activity range, error in the measurements increased to 10%, which is 
still within ANSI recommended tolerance. The measurement results showed that the responses 
from these two detectors do not correlate well in the activity range of 70 to 450 kBq, even 
though both detectors were calibrated for efficiency and energy resolution according to their 
respective recommended methods. The Monte Carlo model developed herein corrects NaI(Tl) 
measurements, allowing for a more accurate estimate of
 225
Ac and daughter activities over a 
range of activities useful for both pre-clinical and clinical use.  
 
3.5 Conclusions 
In this work, the 
225
Ac activity response function between two commonly used instruments 
was investigated, a range of activities (70 to 450 kBq) was identified, and a method was 
developed using Monte Carlo simulations to correct scintillation detector measurements within 
this range. The scintillation detector was calibrated in energy and efficiency using NIST-
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traceable sources covering a broad energy range, while the ion chamber was calibrated in 
efficiency using a surrogate calibration reference. The error of ion chamber measurements 
increased with decreasing activity, but remained within the ANSI recommended value of 10%. 
The NaI(Tl) performed poorly from 70 to 450 kBq. Therefore, a Monte Carlo model was built to 
correct the NaI(Tl) measurements, thereby providing improved accuracy. The corrections 
provided by the Monte Carlo model will provide a useful tool to make corrections to the activity 
values measured by the well-type NaI(Tl) detector. This allows for the better quantification of 
alpha-particle emitting radiopharmaceuticals and daughter byproducts in pre-clinical and clinical 
studies. In this case, use of scintillation gamma spectroscopy will be the preferred method. 
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CHAPTER FOUR: 
MELANOCORTIN 1 RECEPTOR TARGETED ALPHA-PARTICLE THERAPY FOR 
METASTATIC UVEAL MELANOMA 
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4.1 Introduction  
 Uveal melanoma is the most common primary intraocular malignancy and differs from 
the more common cutaneous melanoma in terms of risk factors, primary treatment, anatomic 
spread, molecular changes and response to systemic therapy 
107,108
.  Patients that develop uveal 
melanoma metastases, primarily in the liver, have a very poor prognosis, with a median survival 
of about one year.  Because uveal melanomas have different characteristic mutations compared 
to cutaneous melanomas, targeted therapies that have been effective for cutaneous melanoma, 
e.g. BRAF, are not indicated 
109
.  Immune checkpoint inhibition therapies that are successful in 
cutaneous melanoma have had poor efficacy in ocular melanoma with less than 10% of patients 
responding and with rapid recurrence 
109
.   
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The melanocortin 1 receptor (MC1R) is highly expressed in uveal melanoma metastases 
110
.  MC1R is a member of a family of five G protein coupled melanocortin receptors, four of 
which bind melanocyte-stimulating hormone (MSH) and related ligands (MC1R, 3R, 4R & 5R) 
111
.  Unlike the other members of this G protein family, MC1R is not expressed in most normal 
human tissues 
112
, lessening concern for therapy-related toxicity.  Although expression is found 
in the brain 
113
 and normal melanocytes 
114
, this is not a major concern as conjugates can be 
designed to not cross the blood brain barrier and in the most severe cases of melanocyte loss, the 
most serious symptom is vitiligo 
115
.  MC1R expression has been reported on activated 
monocytes, macrophages and dendritic cells derived from monocytes 
116
.  This is also not a 
significant concern since the population of activated monocytes and macrophages can be 
replenished within days and lymphoid dendritic cells, which do not express MC1R, will not be 
depleted.  MC1R is highly polymorphic 
117
, but the wild-type frequency is ~50% 
114
 and the most 
common mutations occur with a frequency of 21.5% in cytoplasmic domains, 19.7% in 
transmembrane domains and 0% in the extracellular domain 
117
.  Hence, a large majority of 
patients will have an MC1R isoform that is suitable for ligand binding.  A MC1R specific ligand 
(MC1RL) and conjugates were previously developed with high specificity (>200 fold) and 
affinity (0.2-0.4 Nm Ki) for MC1R 
118,119
.  A fluorescent-dye conjugate was rapidly internalized 
by MC1R expressing tumor cells, does not cross the blood brain barrier and is rapidly cleared 
from circulation 
113
.   
Herein is reported the preclinical development and testing of a novel MC1R targeted 
radiopharmaceutical, 
225
Ac-DOTA-MC1RL, for targeted α-particle therapy (TAT)120,121 of uveal 
melanoma.  Alpha-particle emissions consist of di-cationic helium nuclei (He
2+
) that have high 
linear energy transfer and a short mean free path of only a few cell diameters (< 100  µm) in 
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tissue 
122
.  
225Ac is an α-particle emitting radionuclide that has a 10 day half-life 123, four α-
emissions in its decay chain and high (28 MeV) total energy release 
124
.   
 
4.2 Materials and Methods 
4.2.1 Compound Synthesis and Loading with Lanthanide 
 MC1RL 
119
 was synthesized according to a conventional N
α
- 
Fluorenylmethyloxycarbonyl (Fmoc) peptide synthesis strategy, except the Fmoc-Lys(Alloc)-OH 
was coupled to allow orthogonal alloc deprotection of the linker on the epsilon amino group of 
the lysine following the linear peptide synthesis.  The alloc group is removed and Fmoc-
aminohexanoic acid linker and tri-t-butyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate 
(DOTA, TCI) were coupled sequentially using O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HCTU) activation.  The DOTA-MC1RL peptide was 
cleaved from the resin with a cocktail of trifluoroacetic acid (TFA, Chem-Impex International), 
water (H2O), and triisopropylsilane (TIS, Sigma-Aldrich) (95:2.5:2.5, v/v), precipitated in cold 
diethyl ether, pelleted/decanted, and lyophilized.  The crude white powder was purified by a 
reverse-phase high-performance liquid chromatography (HPLC, Agilent) and characterized by 
both MALDI-TOF mass spectroscopy (JEOL) and analytical HPLC.  A scrambled peptide ligand 
(DOTA-SP) was synthesized by changing the order of amino acids (sequence: 4-Phenylbutyric 
Acid-Trp-Gly-His-Arg-(D)-Phe-Lys(Aminohexanoic Acid-DOTA)-CONH2).  The Eu-DTPA-
MC1RL was synthesized as described before 
125
 except that MC1RL was used as the binding 
ligand.  Competition binding assays were performed as previously described using the Eu-
DTPA-NDPα-MSH ligand. The Eu-DTPA-MC1RL binding affinity was determined using 
saturation binding assays.  To determine MC1RL binding affinity for murine MC1RL, saturation 
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binding assays were performed using the Eu-DTPA-MC1RL and B16-F10 murine melanoma 
cells with high expression of murine MC1R 
118
.   
 
4.2.2 Cell Culture and Characterization 
 Uveal melanoma cell lines were acquired: (OCM1, OCM3 and OCM8 from Dr. Kan-
Mitchel, University of Southern California; OMM1 from Dr. Gregorius P. Luyten, University 
Hospital at Rotterdam; and MEL270, MEL290 and OMM2.3 from Timothy Murray, Bascom 
Palmer Eye Institute), and grown in RPMI medium, 10% fetal bovine serum, 100 units/Ml 
penicillin, 100 mg/Ml streptomycin, 1% 200 Mm L-Glutamine, 1% 100 Mm sodium Pyruvate, 
1% MEM Essential Vitamin Mixture (100X), 1% NEAA Mixture (100X) and 1% 1M HEPES in 
5% CO2 at 37°C.  A375, A375/MC1R human cutaneous melanoma cells and Hek293/MC1R 
cells were obtained and grown as before 
118,126
. Cells were authenticated per American Type 
Culture Collection (ATCC) guidelines 
127
, monitored for original morphology, tested for 
mycoplasma (MycoAlert kit, Lonza) and only passage numbers <25 cells were used.  MC1R 
expression and receptor number were determined as previously described 
118,119
 except that Eu-
DTPA-MC1RL was used for saturation binding.  
 
4.2.3 Radiochemical Synthesis and Characterization 
  DOTA-MC1RL or DOTA-SP (10 μg/10 Μl water), 225Ac(NO3)3 (3.4 MBq), 90 Μl of 
water and 10 Μl of 20% L-ascorbic acid were added to a 1.5 Ml tube followed by Ph adjustment 
to 5.5-6 (1 M Tris buffer;10-12 Μl) and incubation at 60ºC for 1 h (Figure 15).   
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Figure 12. Radiochemical synthesis of 
225
Ac-DOTA-MC1RL.
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Specific activity was calculated using a standard method 
128
.  Radiochemical purity was assessed 
24 h after collection by gamma counter and in vitro serum stability was determined by adding 50 
µL of 
225
Ac-DOTA-MC1RL (2072 kBq) to 1 ml of human serum (n=4), incubated at 37°C for 10 
days and quantified at multiple time points by TLC scanner and gamma-counter using 
established methods 
129
.   
 
4.2.4 Animal Studies 
  All protocols were approved: University of South Florida IACUC protocol IS00000805 
and Wake Forest University Health Sciences IACUC protocol A11-144.   Male and Female 
animals were used.  Sprague-Dawley rats, 10-12 weeks old, 200-250 g were purchased with 
jugular vein catheters installed (Charles River).  Non-tumor studies used BALB/c mice (10-12 
weeks, 18-22 g, Charles River).  Severe combined immunodeficient (SCID) mice (6-8 weeks, 
15-20 g, Charles River) were used for xenografting cell lines.  Tail vein catheters were used for 
agent administration to mice.  
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 For xenografting, 1 × 10
6
 cells in 80 µl of PBS and 20 µl of Matrigel (phenol red free, 
Corning) were injected subcutaneously into the flank.  Tumor volumes were determined by 
caliper using the formula:  volume = (length × width
2
)/2 for A375 and A375/MC1R, and volume 
= (length × width × height)/2 for MEL270 tumors, which were initially flat with a gradual shift 
to a rounded shape.  
 
4.2.5 Histology and Immunohistochemistry (IHC) 
   Excised tissues were prepared for histology, hematoxylin and eosin (H&E),  MC1R IHC 
staining, and slide scanning were performed as previously described 
118
.  Metastasis burden was 
determined using images of 3 sections (25%, 50% and 75%) through each liver and lung.  
Metastasis area was determined by segmentation using intensity and size threshold classifiers on 
the triple red channel (Visiopharm software version 6.7.0.2590, Denmark), total tissue area was 
determined with an intensity threshold classifier on the I intensity channel and the percent 
metastasis calculated.   
 To quantify MC1R expression in tumors, images from serial H&E and IHC sections were 
analyzed using Visiopharm 2017.7.  Each serial section pair (H&E and IHC) were aligned using 
the tissue align module and viable tumor segmented by thresholding the hematoxylin 
channel.   A multi-threshold marker area analysis was then performed within the viable tumor 
region on each IHC image.  Each pixel was placed into 4 categories (Negative, Weak, Moderate, 
Strong) based on thresholds set by a pathologist and percentages of each category were 
normalized by total area of interest.    
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4.2.6 Maximum Tolerated Dose (MTD) 
 The MTD study was performed as previously described 
129
.   
 
4.2.7 Measurement of Activity 
  Since α-particles from 225Ac cannot be directly measured in tissue due to the short mean 
free path 
124
, 
225Ac α-activities were estimated using measurements of related gamma emissions.  
For the initial MTD study, syringes were prepared with a range of activities as determined by the 
gamma counter (Wallac 1470 Wizard , Perkin-Elmer).  For subsequent studies, syringes were 
prefilled with 148 kBq ±10% (per appendix E of the BioDex manual) of 
225
Ac-conjugate activity 
using a dose calibrator (BioDex Atomlab 500). Activities were measured for 2 mins using dial 
number 38.2 as recommended by Biodex.  Activities of 
225
Ac, and the 
221
Fr and 
213
Bi daughter 
products 
124
 were measured by acquiring isomeric gamma spectra (Figure 9) prior to 
administration using a 4π well-type wipe-test gamma counter (BioDex Atomlab 500).  Activities 
(
225Ac) were calculated using factors for gamma ray abundance per α-decay using calibration 
parameters and correction coefficients from Appendices A and E of the instrument manual.  A 
full energy window (0-800 keV) was used for spectra acquisition that included gamma counts 
from 
225
Ac (99.8 keV peak, 1% abundance), and two gamma emitting daughters, 
221
Fr (218.1 
keV peak, 11.4 % abundance) and 
213
Bi (440.5 keV peak, 25.9 % abundance) 
130.  The α-
activities were determined by fitting each peak with a multi-Gaussian fit and integrating to 
determine the net number of counts while incorporating the acquisition time.  Spectra were 
acquired ≥24 h post-radiosynthesis or tissue rendering ensuring that 225Ac and daughters were in 
secular equilibrium 
131
.  Activity remaining in the syringe and catheter post-injection were 
calculated and subtracted to determine net administered activity.   
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4.2.8 Blood Pharmacokinetics  
  Sprague-Dawley rats were weighed prior to injection with radioactivity and injected 
with 148 kBq (±10%) of 
225
Ac-DOTA-MC1RL in the syringe.  Serial blood draws (45 µL) were 
taken from 5 min to 24 h post-injection (p.i.).  
225Ac α-activity was calculated as described 
above.  Data were fitted using an exponential decay nonlinear regression.   
 
4.2.9 Biodistribution  
  Non-tumor bearing BALB/c mice, or SCID mice bearing MEL270 xenografts (160-650 
mm
3
), or A375 and A375/MC1R bilateral xenograft tumors (189-1680 mm
3
) were intravenously 
administered 148 kBq (±10%) of 
225Ac α-activity in the syringe.  Tissues were rendered and 
weighed at multiple time-points between 24 h to 3 weeks p.i..  For each tissue, 
225
Ac, 
221
Fr and 
213Bi α-activities were calculated as described above and reported as percent injected activity per 
gram (%IA/g).   
 
4.2.10 Radiation Dosimetry (RD) 
 Tissue BD data for the different tissues were fitted using an exponential decay nonlinear 
regression and dosimetry calculations were performed for 
225
Ac, 
221
Fr , 
217
At, 
213
Bi, and 
213
Po 
using the generalized internal dosimetry schema of the Medical Internal Radiation Dose (MIRD) 
Committee for α-particle emitters 46,132.  The β- decay branching ratio for 217At to 217Rn is only 
0.01%, therefore it was assumed that all decays of 
217At were by α-emission to 213Bi.  The 
branching ratios for decay of 
213
Bi to 
213
Po (98%) or 
209
Tl (2%) were included in the calculation.  
Due to the relatively low linear energy transfer  and the small dimensions of the target tissues, 
the β- emissions from 217At, 213Bi, 209Tl and 209Pb were assumed negligible and were not included 
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in the calculations 
133
.  The following assumptions were made:  1) uniform distribution of 
activity in the tissue volume; 2) no α-particles escaped from the source tissue due to the short 
range; and 3) electron and photon contributions were assumed to be negligible compared to α-
particle energy deposition 
133.  It was also assumed that α-particles from 221Fr (4.9 min T1/2),
 
217
At (32.2 ms T1/2 ), 
213
Bi (46 min T1/2) and 
213
Po (4.2 µs T1/2) were deposited in the same 
location as 
225
Ac (10 d T1/2) due to the relatively shorter half-lives of these daughter isotopes.  
Although 
217
At and 
213
Po do not have detectable gamma emissions, under the assumption that the 
decay chain had reached secular equilibrium, the accumulated activity of these two daughters 
would equal that of 
221
Fr and 
213
Bi, respectively.  The total absorbed α-particle dose was 
calculated from the summation of doses from 
225
Ac, 
221
Fr, 
217
At, 
213
Bi and 
213
Po.   
 
4.2.11 Anti-tumor Efficacy 
 Tumor bearing mice (n=11/group) were injected with activities of 
225
Ac-DOTA-MC1RL 
or 
225
Ac-DOTA-SP, cold La-DOTA-MC1RL, or saline solution (0.9%, Cardinal 
Pharmaceuticals).  Surpassing 2000 mm
3
 tumor volume was the experimental endpoint unless 
clinical endpoints, e.g. 20% weight loss, tumor ulceration, hunched back, lack of grooming or 
lethargy were observed.  Metastasis formation was identified by necropsy. 
 
4.2.12 Statistical Analysis 
The T-test was used for the MTD study.  The following analyses were used for 
comparison of the efficacy study groups:  Kaplan-Meier for time to endpoint, a mixed model 
analysis for tumor growth change, a paired Wilcoxon Signed Rank test for initial decrease in 
tumor volume, the Fisher’s Exact test with corrections for multiple testing using the Holm 
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stepdown method for metastasis burden, and non-parametric Kruskal-Wallis test for IHC 
staining.  
 
4.3 Results 
4.3.1 Synthesis and Characterization of Parent Compound and Lanthanide Chelates 
The unmetallated DOTA-MC1RL was synthesized and, since there are no non-
radioactive isotopes of Ac, the analogous La-DOTA-MC1RL chelate was prepared for use as a 
non-radioactive control 
129,134
.  Both DOTA-MC1RL and La-DOTA-MC1RL had high binding 
affinity for human MC1R, 0.24 ± 0.20 and 0.23 ± 0.18 Nm Ki respectively (Supplemental Fig. 
9A).  The binding affinity of Eu-DTPA-MC1RL to human MC1R was determined to be 4.4 ± 2.3 
Nm Kd. Lower, 1.3 µM Kd affinity was observed for Eu-DTPA-MC1RL binding to murine 
MC1R. The scrambled peptide controls, La-DOTA-SP and Eu-DOTA-SP, did not bind.  
 
4.3.2 Radiosynthesis and Characterization of 
225
Ac Radiopharmaceutical  
Radiochemical purity of 99.8% and specific activity of 181.3 ± 92.5 kBq/µg and 140.6 ± 
55.5 µkBq/µg for 
225
Ac-DOTA-MC1RL and 
225
Ac-DOTA-SP, respectively, were observed. In 
vitro serum stability was high, with 90% intact after 10 days (Table 4) 
Table 4.  In vitro serum stability of 
225
Ac-DOTA-MC1RL.
76
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4.3.3 MC1R Expression on Uveal Melanoma Cell Lines and Xenograft Tumors 
MC1R Mrna and protein expression were confirmed in a set of uveal melanoma cell 
lines. Only MEL270, OMM2.3 and OMM1 cells carry the GNAQ or GNA11 mutations found in 
nearly all uveal melanomas 
135
.  The MEL270 and OMM1 cells formed tumors in 
immunocompromised mice and all xenografts had high and uniform MC1R protein expression. 
 
4.3.4 Receptor Number for Tumor Cell Lines 
MEL270 cells were selected for the in vivo studies and it was determined that MEL270 
cells have 410,000 receptors per cell, which is a higher level of endogenous expression than the 
engineered A375/MC1R cells that have 75,000 receptors per cell 
118
.  The parental A375 
melanoma cell line has extremely low expression with 400 ± 93 MC1R per cell 
136
.   
 
4.3.5 In vitro MC1R-specific Cytotoxicity  
Cytotoxicity assays were performed with the goal of demonstrating target-specific 
cytotoxicity.  Assay conditions were not optimized to demonstrate maximal toxicity.  
Significantly reduced proliferation (p < 0.0001) was observed in uveal melanoma cells and the 
engineered A375/MC1R cells treated with 
225
Ac-DOTA-MC1RL relative to the untargeted 
225
Ac-DOTA-SP or PBS controls. All cell lines also had a significant (p < 0.001) response to 
incubation with 
225
Ac-DOTA-SP relative to PBS.  However, there was no significant difference 
in A375 cell proliferation (extremely low MC1R) when treated with either the targeted or 
untargeted radiopharmaceutical.  These results demonstrate MC1R-specific cytotoxicity.  Assay 
replicates yielded comparable results.   
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4.3.6 Maximum Tolerated Dose (MTD) 
The MTD was evaluated in immune-competent non-tumor bearing BALB/c mice (n = 
5/cohort).  Cohorts received a single i.v. injection of 
225
Ac-DOTA-MC1RL over the range of 0-
148 kBq in the syringe.  At completion of the study (>11 
225
Ac half-lives, 118 days post 
injection) serum and tissues (adipose, bone, cecum, colon, duoden, esophageal, heart, ileum, 
kidney, liver, lung, lymph nodes, muscle, pancreas, small intestine, spleen and stomach) were 
collected for histology and then blindly examined by a veterinary pathologist to assess radiation-
induced tissue damage.  There was no remarkable damage observed in any of the tissues, e.g. the 
control kidneys had minimal multifocal interstitial fibrosis and minimal medullary protein in 
tubules which were both considered to be incidental findings.  The incidental minimal medullary 
protein was also found in some kidneys from the groups that received treatment activities, but 
each treatment group also included kidneys that were within normal limits of all types of 
damage. The renal cortex of one kidney from the group with the highest administered activity 
had focal extracellular cortical hyaline substance which was healing and was considered to be an 
incidental finding. Blood urea nitrogen (BUN) and creatinine, which are important indicators of 
renal function, were also determined and were not significantly elevated among the groups 
(Figure 16 B&C).  All animals had gained weight by the end of the study, albeit less weight was 
gained by animals at the highest dose level relative to the lowest (Figure 13A).   
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Figure 13.  MTD study for non-tumor bearing mice:  (A) Percent weight gain, (B) BUN and (C) 
blood creatinine.
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4.3.7 Pharmacokinetics and Biodistribution  
In rats, 
225
Ac-DOTA-MC1RL rapidly cleared (<15 min p.i.) from blood circulation 
(Figure 14).   
 
Figure 14.   Plot of rat blood clearance.  Exponential decay non-linear regression line fit of 
225
Ac 
alpha activity in rat blood over time, following intravenous administration of 
225
Ac-DOTA-
MC1RL (n=4 rats).
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Following administration to non-tumor bearing BALB/c mice, 
225
Ac activities were 
observed primarily in clearance tissues.  At 24 h p.i. of 
225
Ac-DOTA-MC1RL, the liver, kidneys, 
spleen and intestine had 21.2 ±2.8, 6.9±0.9, 2.9±0.8 and 2.9±2.0 %IA/g, while negligible activity 
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was observed in the other tissues measured. Activity had largely cleared from the tissues in 1-3 
weeks (Figure 15A).   
 
Figure 15.  Biodistribution of 
225
Ac-DOTA-MC1RL.  
225
Ac, 
221
Fr and 
213
Bi activities in tissues 
from (A) non-tumor bearing BALB/c mice (n=6 per time point) and (B) SCID mice bearing 
MEL270 human uveal melanoma tumors (n=5 per time point).
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For tumor-bearing animals, activity was retained in MC1R positive tumors, i.e. MEL270 (Figure 
15B) and A375/MC1R tumors (Figure 16A) that had 3.6±1.2 and 2.8±0.8 %IA/g, respectively, 
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compared to the nominal 0.30±0.1 %IA/g in the MC1R negative A375 tumors at 24 h post- 
injection.  The clearance tissues in tumor bearing animals had lower activities compared to 
clearance tissues in the non-tumor bearing mice, e.g. 14.4±1.7 %IA/g in the livers of MEL270 
tumor-bearing mice at 24 h (Figure 15B), compared to the 21.2 ±2.8 %IA/g observed in the non-
tumor bearing mice (Figure 15A).   The 
225
Ac-DOTA-SP tumor distribution in the bilateral A357 
and A375/MC1R model was also determined and, as expected, uptake was minimal and did not 
differ among the positive and negative A375 tumors (Figure 16B).   
 
 
Figure 16.  Biodistribution of (A) 
225
Ac-DOTA-MC1RL and (B) 
225
Ac-DOTA-SP in bilateral 
A375 and A375/MC1R tumors (n=5 per time point).
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The distribution of 
221
Fr and 
213
Bi were also determined (Figures 15 & 16).  However, since 
225
Ac and daughters are at secular equilibrium by 24 h p.i. and the 
221
Fr and 
213
Bi atoms present 
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during injection will be mostly decayed, the 
221
Fr and 
213
Bi detected in the samples are from 
decay of the 
225
Ac taken into the tissues.  
 
4.3.8 Radiation Dosimetry  
 BD data were fitted, and clearance kinetics, tissue biological half-life, accumulated 
activity, and absorbed dose/injected activity (Gy/kBq) were estimated for each radionuclide in 
each tissue for non-tumor bearing and MEL270 tumor bearing mice (Tables 5&6).  
Table 5. Radiation dosimetry and clearance kinetics parameters for 
225
Ac-DOTA-MC1RL in 
non-tumor bearing BALB/c mice.
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                                    225
Ac 
 Parameter Blood Brain Heart Intestine Kidney Liver Lung Muscle Skin Spleen 
 Initial activity/organ, A
o
 (kBq) ND 0.0065 0.0161 1.9113 0.7647 7.6597 0.0512 0.0044 0.0483 0.0426 
 Decay rate constant, λ
eff
 (h
-1
) ND 0.0070 0.0030 0.0060 0.0060 0.0040 0.0030 0.0030 0.0050 0.0030 
 Decay half-life, T
eff
 (days) ND 4.1259 9.6270 4.8135 4.8135 7.2203 9.6270 9.6270 5.7762 9.6270 
 Accumulated activity/organ, Ã (kBq*h) ND 0.7621 3.8089 260.3419 104.1599 1484.6038 12.1242 1.0529 7.7927 10.0784 
 Absorbed dose/injected activity (Gy/kBq) ND 0.0002 0.0023 0.0102 0.0300 0.1485 0.0042 0.0004 0.0024 0.0092 
                                                  221
Fr 
 Parameter Blood Brain Heart Intestine Kidney Liver Lung Muscle Skin Spleen 
 Initial activity/organ, A
o
 (kBq) 0.0153 0.0222 0.0349 1.9927 1.3795 8.4464 0.0723 0.0211 0.0705 0.0647 
 Decay rate constant, λ
eff
 (h
-1
) 0.0010 0.0030 0.0050 0.0070 0.0080 0.0040 0.0020 0.0030 0.0040 0.0040 
 Decay half-life, T
eff
 (days) 28.8811 9.6270 5.7762 4.1259 3.6101 7.2203 14.4406 9.6270 7.2203 7.2203 
 Accumulated activity/organ, Ã (kBq*h) 5.6907 5.2622 5.6292 232.2869 139.2517 1637.0734 21.2642 4.9899 13.6614 12.5317 
 Absorbed dose/injected activity (Gy/kBq) 0.0022 0.0013 0.0037 0.0098 0.0434 0.1770 0.0080 0.0018 0.0045 0.0124 
                                                 217
At 
 Parameter Blood Brain Heart Intestine Kidney Liver Lung Muscle Skin Spleen 
 Initial activity/organ, A
o
 (kBq) 0.0153 0.0222 0.0349 1.9927 1.3795 8.4464 0.0723 0.0211 0.0705 0.0647 
 Decay rate constant, λ
eff
 (h
-1
) 0.0010 0.0030 0.0050 0.0070 0.0080 0.0040 0.0020 0.0030 0.0040 0.0040 
 Decay half-life, T
eff
 (days) 28.8811 9.6270 5.7762 4.1259 3.6101 7.2203 14.4406 9.6270 7.2203 7.2203 
 Accumulated activity/organ, Ã (kBq*h) 5.6907 5.2622 5.6292 232.2869 139.2517 1637.0734 21.2642 4.9899 13.6614 12.5317 
 Absorbed dose/injected activity (Gy/kBq) 0.0025 0.0014 0.0042 0.0110 0.0486 0.1983 0.0090 0.0021 0.0050 0.0139 
                                              213
Bi 
 Parameter Blood Brain Heart Intestine Kidney Liver Lung Muscle Skin Spleen 
 Initial activity/organ, A
o
 (kBq) 0.0236 0.0195 0.0309 1.8886 1.0318 6.5122 0.0717 0.0152 0.0627 0.0511 
 Decay rate constant, λ
eff
 (h
-1
) 0.0010 0.0010 0.0020 0.0050 0.0040 0.0040 0.0020 0.0020 0.0030 0.0030 
 Decay half-life, T
eff
 (days) 28.8811 28.881 14.4406 5.7762 7.2203 7.2203 14.4406 14.4406 9.6270 9.6270 
 Accumulated activity/organ, Ã (kBq*h) 8.7917 7.2573 9.0914 304.6111 199.9839 1262.1858 21.0948 4.4603 14.8376 12.1064 
 Absorbed dose/injected activity (Gy/kBq) 0.0001 0.0000 0.0001 0.0002 0.0012 0.0025 0.0001 0.0000 0.0001 0.0002 
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Table 5. (Continued) 
 
The effective decay half-lives (Teff) calculated for 
225
Ac in tissues, e.g. 7.2 d in liver, were 
shorter than the radiodecay half-life of 
225
Ac (10 d) indicating biological clearance.  The 
calculated total absorbed dose per injected activity (Gy/kBq) for 
225
Ac-DOTA-MC1RL was 
minimal in all tissues except clearance organs and positive tumor. Since the positive tumors 
shrank rapidly in response to the treatment and the total absorbed dose values were extrapolated 
from data collected over a two week period, the dose values for the tumors are likely subdued 
relative to the clearance organs which did not have appreciable cellular toxicity at the 
administered activities. The total absorbed dose in the liver was generally lower in mice with 
tumors compared to non-tumor mice, e.g. 0.284 Gy/kBq and 0.704 Gy/kBq, respectively. 
 
Table 6.  Radiation dosimetry and clearance kinetics for 
225
Ac-DOTA-MC1RL in SCID mice 
bearing MEL270 tumors.
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                                                 213
Po 
 Parameter Blood Brain Heart Intestine Kidney Liver Lung Muscle Skin Spleen 
 Initial activity/organ, A
o
 (kBq) 0.0236 0.0195 0.0309 1.8886 1.0318 6.5122 0.0717 0.0152 0.0627 0.0511 
 Decay rate constant, λ
eff
 (h
-1
) 0.0010 0.0010 0.0020 0.0050 0.0040 0.0040 0.0020 0.0020 0.0030 0.0030 
 Decay half-life, T
eff
 (days) 28.8811 28.881 14.4406 5.7762 7.2203 7.2203 14.4406 14.4406 9.6270 9.6270 
 Accumulated activity/organ, Ã (kBq*h) 8.7917 7.2573 9.0914 304.6111 199.9839 1262.1858 21.0948 4.4603 14.8376 12.1064 
 Absorbed dose/injected activity (Gy/kBq) 0.0044 0.0023 0.0079 0.0168 0.0811 0.1778 0.0103 0.0021 0.0063 0.0156 
 Total absorbed dose/injected Activity (Gy/kBq) 
Blood Brain Heart Intestine Kidney Liver Lung Muscle Skin Spleen 
0.0092 0.0053 0.0183 0.0481 0.2042 0.7042 0.0317 0.0064 0.0182 0.0512 
                                                    225
Ac 
 Parameter Blood Bone Brain Heart Intestine Kidney Liver Lung Muscle Skin Spleen Tumor 
 Initial activity/organ, A
o
 (kBq) 0.0010 0.0172 0.0031 0.0151 0.3026 0.6417 4.8193 0.0265 0.0042 0.0242 0.0228 0.0518 
 Decay rate constant, λ
eff
 (h
-1
) 0.0010 0.0030 0.0020 0.0050 0.0130 0.0050 0.0060 0.0050 0.0020 0.0020 0.0040 0.0080 
 Decay half-life, T
eff
 (days) 28.8811 9.6270 14.4406 5.7762 2.2216 5.7762 4.8135 5.7762 14.4406 14.4406 7.2203 3.6101 
 Accumulated activity/organ, Ã 
(kBq*h) 
0.2726 3.2443 0.6873 2.1154 16.7417 89.9040 588.513 3.7089 0.9236 5.3441 3.6979 4.9055 
 Absorbed dose/injected activity 
(Gy/kBq) 
0.0001 0.0041 0.0003 0.0020 0.0012 0.0273 0.0662 0.0025 0.0007 0.0010 0.0107 0.0045 
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Table 6. (Continued) 
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Fr 
 Parameter Blood Bone Brain Heart Intestine Kidney Liver Lung Muscle Skin Spleen Tumor 
 Initial activity/organ, A
o
 (kBq) 0.0036 0.0185 0.0059 0.0192 0.2655 0.6167 4.4828 0.0495 0.0071 0.0362 0.0257 0.0806 
 Decay rate constant, λ
eff
 (h
-1
) 0.0017 0.0030 0.0010 0.0030 0.0090 0.0040 0.0060 0.0040 0.0020 0.0020 0.0010 0.0070 
 Decay half-life, T
eff
 (days) 16.9889 9.6270 28.8811 9.6270 3.2090 7.2203 4.8135 7.2203 14.4406 14.4406 28.881 4.1259 
 Accumulated activity/organ, Ã 
(kBq*h) 
0.8370 3.4960 1.5396 3.6259 22.3311 99.8475 547.425 8.0162 1.5699 8.0166 6.7303 8.6407 
 Absorbed dose/injected activity 
(Gy/kBq) 
0.0002 0.0047 0.0007 0.0037 0.0017 0.0328 0.0666 0.0058 0.0014 0.0017 0.0211 0.0086 
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At 
 Parameter Blood Bone Brain Heart Intestine Kidney Liver Lung Muscle Skin Spleen Tumor 
 Initial activity/organ, A
o
 (kBq) 0.0036 0.0185 0.0059 0.0192 0.2655 0.6167 4.4828 0.0495 0.0071 0.0362 0.0257 0.0806 
 Decay rate constant, λ
eff
 (h
-1
) 0.0017 0.0030 0.0010 0.0030 0.0090 0.0040 0.0060 0.0040 0.0020 0.0020 0.0010 0.0070 
 Decay half-life, T
eff
 (days) 16.9889 9.6270 28.8811 9.6270 3.2090 7.2203 4.8135 7.2203 14.4406 14.4406 28.881 4.1259 
 Accumulated activity/organ, Ã 
(kBq*h) 
0.8370 3.4960 1.5396 3.6259 22.3311 99.8475 547.425 8.0162 1.5699 8.0166 6.7303 8.6407 
 Absorbed dose/injected activity 
(Gy/kBq) 
0.0003 0.0053 0.0007 0.0041 0.0019 0.0367 0.0746 0.0065 0.0015 0.0019 0.0236 0.0097 
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Bi 
 Parameter Blood Bone Brain Heart Intestine Kidney Liver Lung Muscle Skin Spleen Tumor 
 Initial activity/organ, A
o
 (kBq) 0.0016 0.0133 0.0027 0.0082 0.2160 0.5664 3.9089 0.0175 0.0017 0.0240 0.0131 0.0381 
 Decay rate constant, λ
eff
 (h
-1
) 0.0013 0.0020 0.0007 0.0040 0.0100 0.0040 0.0060 0.0060 0.0020 0.0050 0.0030 0.0060 
 Decay half-life, T
eff
 (days) 22.2163 14.4406 41.2588 7.2203 2.8881 7.2203 4.8135 4.8135 14.4406 5.7762 9.6270 4.8135 
 Accumulated activity/organ, Ã 
(kBq*h) 
0.4096 2.9358 0.7531 1.3342 16.2384 91.7024 477.346 2.1354 0.3859 3.3617 2.4736 4.6565 
 Absorbed dose/injected activity 
(Gy/kBq) 
2.20E-06 7.39E-05 5.96E-06 2.51E-05 2.32E-05 5.61E-04 1.08E-03 2.88E-05 6.19E-06 1.32E-05 1.44E-04 8.68E-05 
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 Parameter Blood Bone Brain Heart Intestine Kidney Liver Lung Muscle Skin Spleen Tumor 
 Initial activity/organ, A
o
 (kBq) 0.0016 0.0133 0.0027 0.0082 0.2160 0.5664 3.9089 0.0175 0.0017 0.0240 0.0131 0.0381 
 Decay rate constant, λ
eff
 (h
-1
) 0.0013 0.0020 0.0007 0.0040 0.0100 0.0040 0.0060 0.0060 0.0020 0.0050 0.0030 0.0060 
 Decay half-life, T
eff
 (days) 22.2163 14.4406 41.2588 7.2203 2.8881 7.2203 4.8135 4.8135 14.4406 5.7762 9.6270 4.8135 
 Accumulated activity/organ, Ã 
(kBq*h) 
0.4096 2.9358 0.7531 1.3342 16.2384 91.7024 477.346 2.1354 0.3859 3.3617 2.4736 4.6565 
 Absorbed dose/injected activity 
(Gy/kBq) 
0.0002 0.0052 0.0004 0.0018 0.0016 0.0392 0.0756 0.0020 0.0004 0.0009 0.0101 0.0061 
 Total absorbed dose/injected Activity 
(Gy/kBq) 
Blood Bone Brain Heart Intestine Kidney Liver Lung Muscle Skin Spleen Tumor 
0.0007 0.0193 0.0021 0.0115 0.0065 0.1366 0.2842 0.0168 0.0040 0.0056 0.0656 0.0290 
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4.3.9 Anti-tumor Efficacy  
SCID mice bearing MEL270 tumors (124±36 mm
3
 pre-treatment tumor volumes) were 
injected with a single administration of 
225
Ac-DOTA-MC1RL (92.5±9.3 kBq), 
225
Ac-DOTA-SP 
(99.9±9.9 kBq), La-DOTA-MC1RL (1 pmol/mouse) or saline.  Representative images show 
much smaller tumors in treated mice relative to controls (Fig. 17A) and tumor volumes 
decreased immediately after treatment relative to controls ( p=0.001) prior to eventual regrowth 
(Figure 17B).  
 
Figure 17.  Efficacy study in mice bearing MEL270 tumors: (A) Representative images of 
tumors (outlined); (B) initial tumor growth volumes; (C) Kaplan-Meier plots.
76
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Treated mice had a significantly delayed time to experimental or clinical endpoint (p < 0.001) 
with a median survival of 148 days, compared to the median survival of control groups (79-108 
d) and differences among the controls were not significant (Figure 17C).  In this study, some 
animals were euthanized due to reaching clinical endpoints instead of the experimental endpoint. 
Some of the animals that reached clinical endpoints had metastases in the liver or lungs and 
metastasis burden was significantly lower in the 
225
Ac-DOTA-MC1RL treated group relative to 
the controls (p = 0.024) (Figure 18 A&B).   
 
Figure 18.  (A-B) Metastasis study in MEL270 uveal melanoma mouse model and (C-D) MC1R 
expression in tumors reaching endpoints from each treatment group. (A) Representative H& E 
staining and corresponding threshold segmentations of sections containing liver and lung 
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metastases (Cold=La-DOTA-MC1RL, Scrambled=untargeted, treated=
225
Ac-DOTA-MC1RL), 
blue=normal tissue and green=metastasis; and (B) quantified metastasis burden.  (C-D) MC1R 
IHC staining of MEL270 tumors after reaching endpoints.
76
 
 
Mice bearing A375/MC1R tumors (240±110 mm
3 
pretreatment volume) were also injected with 
either sterile saline, La-DOTA- MC1RL, 107.3±11.1 kBq of 
225
Ac-DOTA-SP or 59.2±5.9 kBq 
of 
225
Ac-DOTA-MC1RL and significant decreases in tumor volume (p = 0.005) and tumor 
growth delay (p < 0.0001) were observed.  Some tumors that disappeared did not recur and those 
mice lived their natural lifespan. 
 
Figure 19. Efficacy study in mice bearing A375/MC1R tumors:  (A) Representative images of 
tumors (outlined); (B) initial tumor growth volumes; and (C) Kaplan-Meier plots.
76
 
 
After tumors reached an endpoint, MC1R staining was quantified and the level of MC1R 
expression was not significantly different in treated tumors that responded by shrinking prior to 
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regrowth relative to control tumors (p = 0.60 MEL270 and p=0.82 A375/MC1R) (Figure 18 
C&D). 
 
4.4 Discussion  
 We have developed and evaluated a novel MC1R-targeted radiopharmaceutical, 
225
Ac-
DOTA-MC1RL, for TAT of metastatic uveal melanoma.  The choice of using a peptide targeting 
ligand is reinforced by the recent pre-clinical and clinical successes of TAT radio-peptides 
99,120,121,137,138
.  Another group has also reported the development of a peptide-based TAT, 
212
Pb-
CCMSH, that is targeted to melanocortin receptors for treatment of melanoma 
139
.  However, 
212
Pb-CCMSH was associated with renal toxicity.  This is likely due to the use of an α-MSH 
(melanocyte stimulating hormone) derivative targeting ligand as α-MSH has specificity for 
multiple melanocortin receptor isoforms, including MC5R which is expressed in the human 
kidney and lungs 
112
.  The MC1RL targeting moiety used in the current work has specificity for 
the MC1R isoform 
119
, greatly reducing the potential for renal toxicity.  Another advantage of 
225
Ac-DOTA-MC1RL compared to the 
212
Pb-TAT agent, is that 
225
Ac has greater cell killing 
potential through generation of four α-particle emissions per radionuclide compared to the single 
α-emission of 212Pb in their relative decay chains 25,139.   
 
225
Ac-DOTA-MC1RL has high affinity for MC1R, high radiochemistry yield and purity, 
high biostability and MC1R specific cytotoxicity in vitro.  In vivo studies demonstrated low 
toxicity, rapid blood clearance and uptake into MC1R positive tumors and clearance organs.  
Biodistribution studies demonstrated that 
225
Ac remains in the compartments where 
225
Ac-
DOTA-MC1RL was initially distributed, i.e. tumors and clearance organs, and the corresponding 
clearance kinetics parameters and radiation dose delivered by all α-particle emitting 
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radioisotopes in the decay chain were calculated.  Considering the 10 d half-life of 
225
Ac, most of 
the administered 
225
Ac-DOTA-MC1RL will have either been taken into tumor cells 
113
 or cleared 
from the blood prior to decay.  Hence, 
225
Ac-DOTA-MC1RL likely functions as an in vivo α-
particle generator, concentrating α-emissions in the target tumor tissues with limited 
translocation of daughter isotopes 
99
.  This is consistent with the recent observations of efficacy 
with low toxicity observed for an 
225
Ac-PSMA targeting small-molecule conjugate 
140
.   
In vivo efficacy studies demonstrated significant tumor and metastasis growth delay, and 
prolonged survival in human uveal and cutaneous melanoma xenograft models in mice following 
a single treatment of 
225
Ac-DOTA-MC1RL, including some cures.  Tumors that shrank and 
regrew following treatment had the same MC1R expression levels as controls, suggesting that 
multiple treatment regimens would increase efficacy.   
 
4.5 Conclusion 
 We have developed and evaluated a novel MC1R-targeted radiopharmaceutical for TAT 
of metastatic uveal melanoma.  In vivo studies demonstrated low toxicity, rapid blood clearance, 
uptake into MC1R positive tumors and clearance organs, significant tumor and metastasis 
growth delay, and prolonged survival in human uveal melanoma xenograft models in mice 
following a single treatment of 
225
Ac-DOTA-MC1RL.  This novel radiopharmaceutical has 
strong potential to benefit patients with metastatic uveal melanoma, which has had no significant 
improvement in treatment in the last 20 years. 
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CHAPTER FIVE: 
BIODISTRIBUTION AND MULTI-COMPARTMENT PHARMACOKINETIC 
ANALYSIS OF TWO TARGETED ALPHA PARTICLE THERAPIES 
 
5.1 Introduction 
Receptor-targeted cancer therapy using alpha-emitting radionuclides has become an area 
of significant interest for both preclinical and clinical investigation.
141
 The interest in the use of 
alpha particles to treat metastatic cancer arises from their favorable physical interactions in 
tissue, i.e., short path length (50-100µm) and high linear energy transfer (LET) (80-100keV/µm), 
which are the result of their large kinetic energy and 2+ charge.
4
 These properties allow for the 
potential to target disseminated cancer cells through ligand conjugation and create irreparable 
DNA double strand breaks and other intracellular damage while minimizing radiation dose to 
non-targeted tissues. 
The most common ocular malignancy, uveal melanoma, accounts for 85-95% of all 
ocular melanoma cases.
142
  Despite favorable outcomes for local control, the five year survival 
after metastasis is less than 1%, with a median survival time of 3.6 months post diagnosis.
143
 
The melanocortin-1 receptor (MC1R) belongs to the melanocortin family of G protein coupled 
receptors and has been shown to be predominantly expressed by melanoma and 
melanocytes.
144,145
 MC1R has been shown to be overexpressed in malignant primary and 
metastatic uveal melanoma cell lines with insignificant expression in other normal 
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tissues.
112,116,146
 α-Melanocyte stimulating hormone (α-MSH), a tridecapeptide, is the most 
potent naturally occurring melanotropic peptide for the activation of MC1R
147
 and is a potent 
stimulator of the differentiation of pigmented melanoma cells.
144
 Radiolabeled peptide ligands 
based on the sequence of α-MSH have been investigated, however these do not show selectivity 
for MC1R.
146
 An MC1R specific ligand, MC1RL, with high specificity and affinity for MC1R 
has been developed and tested.
148,149
 An MC1R targeted alpha emitting radiopharmaceutical, 
225
Ac-DOTA-MC1RL, has been synthesized and tested in vivo showing promising results for 
clinical translation.
76
 
The quantity of radiopharmaceutical to be administered and resulting absorbed dose may 
be determined based on a prediction of the biodistribution (BD), uptake, and clearance of the 
drug over time in organs and tumors.
150
 Optimization of a radiotherapy consists of maximizing 
tumor control while minimizing normal tissue complications. Pharmacokinetic (PK) modeling 
using pre-clinical and clinical distribution data is a useful tool that can enable optimized 
treatment by estimating transport properties of the radiopharmaceutical.
151
  By segmenting the 
body into compartments which are related through differential equations, and placing measured 
radioactivity concentrations in them, one can make predictions on the effectiveness of the 
radiopharmaceutical. Typically, blood PK measurements are taken over time and a two 
compartment model is constructed and solved with acquired samples.
152
 A novel multi-
compartmental PK model for a targeted alpha therapy could help to compare the BD , predict the 
relative effectiveness of different TAT compounds and provide a basis for rejection early in the 
developmental process.
153
 Many alpha emitting radionuclides cannot be directly imaged for 
biodistribution analysis. The model could be used alongside a companion imaging agent for 
patient specific treatment planning. 
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Two versions of a therapeutic alpha radiopharmaceutical are being investigated: 
225
Ac-
DOTA-Ahx-MC1RL (Ahx) and 
225
Ac-DOTA-di-D-Glu-MC1RL (di-D-Glu). In this study, the 
BD in mice from each was assessed and a computational multi-compartment pharmacokinetic 
PK model was developed to describe drug distribution and elimination rates. 
 
5.2 Materials and Methods 
5.2.1 MC1RL Peptide Synthesis 
The MC1RL peptide with di-D-Glu linker was synthesized on Rink Amide resin (initial loading: 
0.568 mmol/g) using N
α
- Fluorenylmethyloxycarbonyl (Fmoc)-protecting amino acids and O-
(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU)/ 
Diisopropylethylamine (DIEA) strategy. After the resin was swollen in Dichloromethane (DCM) 
for 30 minutes, the Fmoc protecting group was removed with 2% 1,8-Diazabicyclo(5.4.0)undec-
7-ene (DBU) in Dimethylformamide (DMF) (2 × 5 min). The resin was washed with N-methyl-
2-pyrrolidone (NMP) and DCM three times each and the first amino acid was coupled using 
HCTU and DIEA in NMP (4 equiv of N
α
-Fmoc amino acid, 4 equiv of HCTU , and 8 equiv of 
DIEA). The double coupling was performed at all steps under the same coupling condition due to 
the sequence deletion and slower coupling rate in longer sequences. After coupling, the resin was 
washed with NMP (× 3)and DCM (× 3) and any unreacted free amine groups on the resin were 
treated using 50 % acetic anhydride in pyridine for 5 min. After the resin was washed with NMP 
(× 3) and DCM (×  3), the same procedure was repeated for the next amino acid coupling until 
every residue was coupled. 
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5.2.2 Alloc Deprotection 
The Alloc protecting group of C-terminal Lys was deprotected with piperidine (5-10 drops) and 
Pd(PPh3)4 (0.2 equiv) in anhydrous chloroform. Under the nitrogen gas, the reaction mixture was 
stirred for 15 min then repeated. After the resin was washed with chloroform, NMP and DCM, 
the following sequence D-Glu-D-Glu-DOTA was coupled to the free amine via HCTU coupling 
as described above.  
 
5.2.3 Cleavage of Peptide from the Resin 
The peptide and protecting groups were cleaved using cleavage cocktail (88 % Trifluoroacetic 
acid (TFA), 5 % water, 5 % phenol, and 2 % triethylsilane) for 4 h. The crude peptide was 
isolated from the resin by filtration, the filtrate was concentrated, and the peptide was 
precipitated in ice cold diethyl ether, dissolved in water, and lyophilized. The off-white crude 
powder was purified by reverse-phase chromatography. See Figure 20. 
 
Figure 20. Scheme showing synthetic route to metal chelation. 
 
The complexation of 
225
Ac with DOTA-di-D-Glu-MC1RL was performed identically to what has 
been previously described for previously described for 
225
Ac-DOTA-Ahx-MC1RL.
76
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5.2.4 Radiosynthesis of 
225
Ac Radiopharmaceutical 
Radiochemical synthesis and characterization of 
225
Ac-DOTA-Ahx-MC1RL was 
performed as previously described.
76
  
 
5.2.5 Animal Studies 
A375 and A375/MC1R human cutaneous melanoma cells were obtained and grown as 
before.
118
 
Two groups of 16 severe combined immunodeficient (SCID) mice bearing A375 and 
A375/MC1R bilateral xenograft tumors (189-1680 mm
3
) were intravenously administered 148 
kBq (±10%) of Ahx or di-D-Glu.  After injection, 4 groups (n=4) were euthanized at 24, 96, 144 
and 288 hour time points for each cohort. Tumors and 11 other organs including: blood, bone, 
brain, heart, intestine kidney, liver, lung, muscle, skin, and spleen, were harvested at each time 
point. Activities were determined for organs as described previously.
76
 Briefly, isomeric gamma 
spectra were acquired using a 4π well-type wipe-test gamma scintillation detector (BioDex 
Atomlab 500).  Activities were calculated using factors for gamma ray abundance per alpha 
decay using calibration parameters and correction coefficients from Appendices A and E of the 
instrument manual.
92
  A full energy window (0-800 keV) was used for spectra acquisition that 
included gamma counts from 
225
Ac (99.8 keV peak, 1% abundance).
130
  The alpha activities were 
determined by fitting the 
225
Ac peak with a Gaussian fit and integrating to determine the net 
number of counts while incorporating the acquisition time of 30 seconds. BD was then reported 
as percent injected activity per gram (%IA/g). Time activity curves were then calculated for each 
organ. A 5-compartment PK model was built with the following compartments: blood, tumor, 
normal tissue, kidney, and liver (Figure 21 A). 
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Figure 21. A) Schematic of the multi-compartmental pharmacokinetic model. B) The system of 
ODE’s that represent the change in compartmental radioactive concentrations. 
 
This model is characterized by a system of 5 ordinary differential equations (ODE’s) using mass 
action kinetics which describe uptake, inter-compartmental transitions and clearance rates 
(Figure 21 B). 𝐶𝑖 represents radioactive volume concentration in different compartments in 
Bq/mL. The 𝐶𝑛𝑜𝑟𝑚𝑎𝑙 compartment represents the sum of radioactive volume concentrations in 
non-clearance and non-MC1R specific tissues. 𝑘𝑡𝑖, 𝑘𝑡𝑜, 𝑘𝑛𝑖, 𝑘𝑛𝑜, 𝑘𝑘𝑖, 𝑘𝑘𝑜, 𝑘𝑙𝑖, and 𝑘𝑙𝑜are the 
forward and reverse first order transfer rate constants for the tumor, normal tissue, kidney, and 
liver compartments, respectively. 𝑘𝑘𝑒, and 𝑘𝑙𝑒are the first order elimination rate constants from 
the kidney and liver compartments. A bolus injection was assumed at time zero in the 𝐶𝑏𝑙𝑜𝑜𝑑 
compartment. Using Matlab, the ODE’s were simultaneously numerically solved and fit to 
experimental time activity curves using a genetic optimization algorithm. 
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5.3 Results 
5.3.1 Biodistribution 
The time activity curves and biodistribution data were generated and can be seen in Figure 22 
and Figure 23 respectively. 
 
Figure 22. Time activity plots generated for A) Ahx and B) di-D-Glu 
 
 
Figure 23. Biodistribution results for A) 
225
Ac-DOTA-Ahx-MC1RL and B) 
225
Ac DOTA-di-D-
Glu-MC1RL. 
 
Both compounds have minimal distribution to organs at risk other than kidney and liver, which 
are clearance. The Ahx and di-D-Glu had similar kidney uptake at 24 hours of 4.01 %IA/g and 
5.33 %IA/g respectively. The di-D-Glu however had much lower uptake at 24 hours in the liver 
at 1.55 %IA/g compared to 11.49 %IA/g for the Ahx. 
 75 
5.3.2 Pharmacokinetic Analysis 
The fitting of the model solutions to the experimental Ahx biodistribution and di-D-Glu 
biodistribution data with optimization by the genetic algorithm can be seen in Figure 24 and 
Figure 25 respectively. 
 
 
Figure 24. Optimized fitting of compartment solution: Ahx. Note: Compartments were solved 
and fit simultaneously but plotted separately for visualization. 
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Figure 25. Optimized fitting of compartment solution: di-D-Glu. Note: Compartments were 
solved and fit simultaneously but plotted separately for vizualization. 
 
The calculated pharmacokinetic transfer and elimination rates for investigated compounds can be 
seen in Table 7. 
Table 7. PK parameter estimates. All values are [1/hour]. 
Compound kti kto kni kno kki kko kke kli klo kle 
225
Ac-DOTA-Ahx-MC1RL 0.0031 0.0008 0.0130 0.0025 0.0034 0.0035 0.0008 0.1193 0.0227 0.0002 
225
Ac-DOTA-di-D-Glu-MC1RL 0.0026 0.0003 0.0010 0.0057 0.0015 0.0071 0.0002 0.0022 0.0081 0.0001 
 
All of the calculated PK parameter estimates had less than 5% error. From these data, the Ahx 
showed larger and faster uptake in the liver. Both compounds had comparable uptake and 
clearance rates for other compartments.  
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5.4 Discussion 
Several multi-compartment pharmacokinetic models have successfully been designed for 
therapeutic radiopharmaceutical analysis; however these have been limited to applications using 
beta emitters.
153-157
 In this work, the biodistribution and pharmacokinetic behavior for two 
targeted alpha-emitting radiopharmaceuticals targeted to MC1R were investigated.  
Both Ahx and di-D-Glu were preferentially taken into high expressing MC1R tumors 
while negligibly taken into non-clearance organs and low expressing MC1R tumors. While the 
liver showed large uptake of Ahx at 24 hours, these values rapidly decreased to negligible levels 
by the final timepoint. Although lower, the di-D-Glu remained nearly constant in the liver during 
the course of the study. Both compounds showed similar renal uptake at 24h hours, however Ahx 
was more rapidly eliminated from the kidney. Two other peptide MC1R targeted alpha therapies 
have been developed and tested in vivo, 
212
Pb-DOTA-Re(Arg
11
)CCMSH, and  [
212
Pb]DOTA-
MC1L.
71,158
 In the study of both of these compounds, relatively large concentrations of activities 
were found in the kidneys and varying degrees of nephrotoxicity were observed. In the current 
study, neither Ahx, nor di-D-Glu treatment resulted in renal toxicity. 
A PK model was previously developed to analyze the PK of the MC1RL conjugated to a 
near infrared fluorescent dye.
149
 The model from that study was adapted for analysis of the 
targeted alpha therapy described in this work. The findings of the biodistribution analyses were 
reflected in the optimized fitting of the multi-compartment pharmacokinetic model. When the 
obtained transfer and elimination rates were input into the model, the resulting fits to 
experimental data agreed with less than 5% error. The liver uptake rate for the Ahx derivative 
was calculated to be >5 times larger than the intercompartmental transfer rate and 600 times 
greater than the elimination rate. The decrease in activity in the liver then is a result of physical 
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radioactive decay with a small portion being returned to the blood compartment. It was 
previously shown through histology studies, that despite the large uptake in the liver for the Ahx 
compound, no remarkable damage was observed.
76
  
On the other hand, solutions for the di-D-Glu derivative showed much slower uptake, of 
about 50 times less than the Ahx, and much slower reverse transfer rate. This is in agreement 
with the BD analyses. The calculated MC1R tumor uptake rates were similar between the 
compounds. The reverse transfer rate for each was much slower indicating favorable long 
residence times in these tissues. The PK calculations indicate that since there are comparable 
distributions of radioactivity between the compounds, with much less liver uptake for di-D-Glu, 
the injected dose of this derivative could possibly be increased to increase the uptake into MC1R 
positive tumor tissues without toxicity. 
In conclusion, the two targeted alpha therapies tested in this study, 
225
Ac-DOTA-Ahx-
MC1RL and 
225
Ac-DOTA-di-D-Glu-MC1RL showed favorable uptake into MC1R positive 
tissues with no toxicity to other organs of interest. Since the multi-compartment model’s 
solutions agreed with the measured biodistribution data with low error, therapeutic optimizations 
can be considered. The kidney and liver have been identified as the primary dose limiting organs 
for the two derivatives. The PK model can be used to simulate the uptake rates and accumulation 
rates, clearance rates, and absorbed radiation doses to the organs of interest for varying initial 
injection activities and multiple dosing regimens. The model could be used alongside a 
companion imaging agent to predict biodistribution for patient specific treatment planning. This 
analysis will aid in the accurate prediction of the effectiveness of the therapies in patients. 
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CHAPTER SIX: 
DEVELOPMENT OF A THREE DIMENSIONAL VOXEL-BASED MONTE CARLO 
RADIATION DOSIMETRY METHODOLOGY FOR A TARGETED ALPHA 
PARTICLE THERAPY 
 
6.1 Introduction 
The goal of this work is to enable individualized 3D voxel based dosimetry of the 
225
Ac-
DOTA-MC1RL radiopharmaceutical. While there are detectable gamma emissions in the 
225
Ac 
decay chain, SPECT/CT acquisition times required to obtain acceptable counting statistics as a 
result of low gamma emission abundance would be unrealistic in the clinical setting. Therefore, a 
companion imaging tracer needs to be developed with comparable BD properties and 
computational methods need to be developed to convert tracer activity measured to alpha-
emission activities from the 
225
Ac decay chain, followed by dose calculations. In the case of the 
225
Ac-DOTA-MC1RL radiopharmaceutical, 
67
Ga is an ideal SPECT imaging tracer for the voxel-
based dosimetry application, as it is chemically similar to 
225
Ac in terms of charge, is readily 
chelated by DOTA and has a long 3.26 d half-life so that longitudinal post-administration 
acquisitions can be made. MCNP was used to calculate the volume-specific absorbed dose of the 
67
Ga-DOTA-MC1RL tracer. Corresponding ex vivo 
67
Ga-DOTA-MC1RL and 
225
Ac-DOTA-
MC1RL BD/PK activity measurements and MIRD-calculated dosimetry data from the same 
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animal models and time-points were then used to optimize the simulations and evaluate its 
accuracy. 
 
6.2 Materials and Methods 
6.2.1 Biodistribution and Mean Organ Dosimetry Studies 
Sixteen SCID mice were intravenously injected with 18.5 Mbq of 
67
Ga-DOTA-MC1RL 
in the syringe. The method of net injected activity determination was conducted as described for 
225
Ac-DOTA-MC1RL. Three groups (n=4) were euthanized at 24, 48, and 96 hour time points. 
Thirteen organs were harvested at each time point. Organ activities were determined using the 
Biodex scintillation detector. Spectra were obtained and fitted with multi Gaussian fits. The 
computational model of the NaI(Tl) detector described in Section 2.1.2 was used to simulate the 
67
Ga gamma spectrum and determine the detector correction factor. The activity at each 
timepoint was calculated by integrating each photopeak, applying the corresponding detector 
efficiency and abundance at the energy of each photopeak, and summing. The activities at each 
time point were averaged, and the biodistribution was calculated and presented a %IA/g. Tissue 
BD data for the different tissues were fitted using an exponential decay nonlinear regression and 
mean absorbed dose calculations were performed using the MIRD methodology.
46
 Since 
67
Ga is 
a gamma emitter, the assumption that all emissions remain in source location fails and absorbed 
fractions need to be considered.
159
 Monte Carlo pre-calculated S-values obtained from the Mouse 
Whole-Body (MOBY) phantom for 
67
Ga were used to in these calculations.
160
 The absorbed dose 
in each target organ was calculated as the summation of contributions from all source organs, 
including the target organ as a source organ. 
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6.2.2  Development of Voxel-Based Dosimetry 
6.2.2.1      CT to MCNP Conversion Algorithm 
In order to develop the voxelized dosimetric algorithm, a preliminary CT dataset was 
acquired on a clinical CT scanner of the Electron Density Phantom (EDP, Sun Nuclear Corp.). 
The EDP consists of a zero HU Solid Water® disk the size of an average human pelvis. Sixteen 
insert chambers in the disk are designed to be used with interchangeable sets of Tissue 
Mimicking Materials (TMM), including 13 different materials with a wide range of electron 
density values (lung, breast, zero solid water, liver, brain, inner bone, bone, cortical bone, true 
water, adipose, and optional bones with different mineral composition). To inform the Monte-
Carlo model of the elemental composition of a given volume that corresponds to a specific HU 
value, electron densities of specific volumes were linked to HU values determined in the TMM’s 
and HU-ED calibration curves were generated. EDP inserts have well known electronic densities 
and material composition. A material library containing elemental composition and electron 
densities was created. ROIs in the phantom CT images were contoured using Mirada Medical 
software. The external boundary of the whole EDP was also segmented so that radiation dose to 
the rest of the phantom can be calculated and the photon and electron scattering will be properly 
simulated.  
The CT dataset and DICOM tags were read and stored using MATLAB. MCN6.2 has the 
capability to define repeated structures as a lattice. The lattice defines an array of indexed 
hexahedra prisms that can fill any structure in the geometry. Lattice elements with similar 
properties, such as materials can be grouped together into “universes”. Therefore, the geometry 
of the entire CT dataset can be defined using several DICOM tags found in the headers of the 
CT. The ImagePositionPatient tag defines the Cartesian coordinate of the center of the upper-left 
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most voxel of the first slice of the dataset. PixelSpacing and SliceThickness define the 
dimensions of each voxel, while Height, Width, and Slices define the number of voxels in the x, 
y and z directions in the dataset. Using these tags, the boundaries of the dataset were defined in 
MCNP which was then filled with a lattice describing the voxels. 
The dataset was stored in MATLAB as a 3D matrix where each element is a voxel 
containing its grayscale intensity value. To interpret these intensities in a physical manner, the 
values were linearly transformed to Houndsfield Units (HU) using the RescaleSlope and 
RescaleIntercept DICOM tags. The HU scale was segmented in to ranges that represent the 
radiodensities of the TMM of the EDP phantom.
161
 The material definitions are shown in Table 
8. 
Table 8. The materials and corresponding densities and elemental compositions used in 
dosimetric calculations.
162
 
 
   
Chemical Composition (% by mass) 
ID Material HU Range 
Density 
(g/cm3) 
H 
(Z=1) 
C 
(Z=6) 
N 
 (Z=7) 
O 
 (Z=8) 
Na 
(Z=11) 
Mg 
(Z=12) 
P 
(Z=15) 
S 
(Z=16) 
Cl 
(Z=17) 
Ar 
(Z=18) 
K 
(Z=19) 
Ca 
(Z=20) 
1 Air <-800 0.001225 - - 0.755636 0.231475 - - - - - 0.012842 - - 
2 Lung -799 – -200 0.26 0.103 0.105 0.031 0.749 0.002 - 0.002 0.003 0.003 - 0.002 - 
3 Fat -199 –50 0.9 0.114 0.598 0.007 0.278 0.001 - 0.001 0.001 - - - - 
4 Water -49 – 50 1 0.111 - - 0.889 - - - - - - - - 
5 Muscle 50 -280 1.05 0.102 0.143 0.034 0.71 0.001 - 0.002 0.003 0.001 - 0.004 - 
6 Bone >281 1.6 0.034 0.155 0.042 0.435 0.001 0.002 0.103 0.003 - - - 0.225 
 
The entire CT dataset was defined as integer values representing each material. Each element of 
the same material designation was defined as a universe, which then filled the defined lattice. 
The geometrical and material definitions were written to a file compatible for MCNP input. 
 
6.2.2.2     ROI Extraction Algorithm 
After the CT dataset was acquired, each TMM was segmented into 13 regions of interest 
(ROI’s) in Mirada. The resulting DICOM structure set (RTSS) file was imported into MATLAB. 
This file contains the series of points in Cartesian space that define each ROI on each CT slice. 
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An affine transformation was applied to map the points of each ROI to specific voxels of the 
corresponding CT dataset.  
 
Figure 26. Affine transformation to map to voxel location. Pxyz are the Cartesian coordinates of 
the voxel, Sxyz are the Cartesian coordinates of the voxel in the top left corner of the dataset, ijk 
are the voxel indices, Δijk are the pixel spacing and slice thickness, and XYZ define the 
directional cosines.    
 
A binary mask was applied to each voxelized ROI with the parameter that if greater than half of 
a given voxel was covered by the line of shortest distance between neighboring points, that voxel 
would return true. 
 
6.2.2.3     SPECT to MCNP Conversion Algorithm 
The absolute activity quantification must be determined for a particular SPECT system 
and isotope to perform image based internal dosimetry. This calibration factor is used to convert 
the reconstructed SPECT voxel values to activity.
163
 A 5 mL polyethylene sphere was filled with 
activity of 
67
Ga and measured in the Biodex ion chamber. SPECT images were immediately 
obtained of the filled sphere in air using the Siemens Inveon two head SPECT scanner with 5-
MWB-1.0 collimators. The SPECT data were reconstructed using the OSEM3D reconstruction 
algorithm with the point spread function model. Effective isotropic voxel size was 0.5 mm. The 
dataset was imported into Mirada where the sphere was contoured into an ROI. The ROI 
extractor was used to voxelize the ROI and sum the SPECT values within the volume. The 
absolute activity calibration factor (in units of Bq/counts) was determined by dividing the 
activity measured in the ion chamber by the sum of the SPECT voxel values. This value was 
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applied to all voxels in the dataset. The indices of each element and corresponding activity value 
of the dataset were then incorporated into the voxelized source definition of the MCNP input. 
 
6.2.3  In vivo Imaging Studies 
After developing the image conversion algorithms using the phantom studies, a clinically 
translatable workflow was designed (Figure 27). 
 
Figure 27. The clinical workflow to perform patient 3D specific dosimetry. 
 
This workflow was applied to a preclinical in vivo experiment described below. 
 
µSPECT/CT images were acquired for three SCID mice at 24, 48, and 96 hour time 
points. CT images were obtained using the Siemens Inveon conebeam CT scanner. Effective 
pixel resolution was 88.0 µm. CT data were reconstructed using Siemens’ OSEM3D 
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reconstruction protocol with no binning. SPECT images were obtained using the Siemens Inveon 
two head SPECT scanner with 5-MWB-1.0 collimators. SPECT data were reconstructed using 
the OSEM3D reconstruction algorithm with point spread function model. Effective isotropic 
voxel size was 0.5 mm. The CT and SPECT datasets were registered manually using Mirada. 
The CT dataset was then resampled to match the 120x120x240 matrix size of the SPECT dataset. 
ROI’s for the kidneys, liver, and external were created for each mouse. The ROI extraction 
algorithm was employed and the whole organ SPECT-calculated 
67
Ga activity was compared to 
measurements in the ion chamber.  For each time point, the CT and SPECT conversion 
algorithms were executed to generate the MCNP input. A full Monte Carlo run was performed 
for each time point with all 
67
Ga gamma emissions above 0.5% abundance defined. Detailed 
photon physics treatments were employed. The detailed physics treatment includes coherent 
scattering, fluorescent photons post photoelectric absorption, and Compton profiles to account 
for electron binding effects
91
. Secondary electrons were produced but assumed to deposit their 
energy locally using the thick target bremsstrahlung model. Energy deposition (F6) tallies were 
placed in every voxel in the geometry within the external contour. The Monte Carlo generated 
dose rate maps for 
67
Ga-DOTA-MC1RL were integrated to obtain total absorbed dose. This was 
compared to total body absorbed dose calculated using the MIRD fixed geometry schema. 
Therapeutic absorbed dose was calculated for 
225
Ac in the kidneys, liver, and total body. 
The 
67
Ga-to-
225
Ac activity conversion was performed using the SPECT derived activity per voxel 
and assuming that the number of 
67
Ga atoms was equal to the number of 
225
Ac atoms at each 
location in the geometry: 
                                                          𝐴225𝐴𝑐 = 𝐴67𝐺𝑎
𝜆225𝐴𝑐
𝜆67𝐺𝑎
                                         Equation (9) 
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resulting in a 3D 
225
Ac activity map. Monte Carlo simulations were performed for the entire 
spectrum of 
225
Ac alpha particle emission. Alpha particles were tracked with the FermiLab 
angular deflection model with Vavilov straggling.
91
 Delta ray production was turned on with and 
tracked with a 1 keV energy cutoff. Bremsstrahlung production and transport were turned on also 
with a 1 keV energy cutoff. The alpha particle tracking energy cutoff was set to 10 keV. 
Absorbed dose calculations were performed for the total body for 
67
Ga and 
225
Ac for each time 
point. Voxelized organ absorbed dose simulations were also performed for 
225
Ac-DOTA-
MC1RL considering only each specific organ resulting in absorbed dose rates at each time point. 
The dose rates were fitted with exponential nonlinear regression and integrated to obtain the total 
absorbed dose in each voxel. The image based mean absorbed dose in each organ was compared 
to the MIRD mean absorbed doses previously calculated. Dose volume histograms (DVH) were 
generated to analyze the 3D dose distributions. All Monte Carlo simulations were performed on 
the high performance computing cluster at Moffitt Cancer Center. The number of histories for 
each simulation was chosen to give tally errors of less than 10% in each voxel. 
 
6.3 Results 
6.3.1  Biodistribution and Mean Organ Dosimetry 
The computational Monte Carlo model of the NaI(Tl) detector described in Chapter III 
was used to simulate the 
67
Ga gamma spectrum and determine the detector correction factor 
(Figure 28 A). The gamma spectrum fitting algorithm was applied to acquired 
67
Ga 
measurements (Figure 28 B). 
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Figure 28. A) Monte Carlo simulated gamma spectrum of 148 kBq of 
67
Ga. B) Representative 
gamma spectrum and fitting of 
67
Ga acquired with the NaI(Tl) scintillation detector. 
 
The NaI(Tl) correction factor was determined to be 5.65. The harvested organs were measured in 
the NaI(Tl) detector and activities determined using the spectrum fitting algorithm. The 
biodistribution is shown in Figure 29. 
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Figure 29. Biodistribution of 
67
Ga-DOTA-MC1RL. 
 
The tissue BD data were fitted using an exponential nonlinear regression and integrated in order 
to obtain the cumulated activity in each organ. Using the pre-calculated S values from the 
MOBY phantom and the MIRD schema, estimations for mean organ absorbed doses were made 
(Figure 30).  
 
Figure 30. Mean 
67
Ga-DOTA-MC1RL absorbed dose. 
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6.3.2 Phantom SPECT/CT imaging 
CT images of the EDP phantom were acquired with a matrix size of 512x512x28 (Figure 
31). Contours were manually drawn around all 13 TMM’s and the external on each relevant 
slice.  
 
Figure 31. Electron Density Phantom. A) CT-image of middle axial slice, B) visible light image 
and C) segmented CT image. 
 
Using the CT to MCNP algorithm, the EDP dataset was converted from DICOM format to the 
MCNP lattice geometry (Figure 32 A). The voxel values were replaced with material/universe 
integer ID values. 
 
Figure 32. A) The MCNP converted EDP dataset. B) The TMM ROI’s in voxel coordinates. 
 
A CB
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The ROI extraction algorithm was implemented on the segmented EDP dataset (Figure 32 B). 
The absolute activity quantification was determined for the Inveon scanner with 
67
Ga. 
The Biodex ion chamber reading of the 
67
Ga activity filled sphere was 234.95 kBq. SPECT 
images of the sphere were acquired and segmented creating an ROI (Figure 33). The ROI 
extraction algorithm was applied and the total counts within the voxels of the ROI were 9339018 
counts. The resulting activity calibration was 0.0252 Bq/count. 
 
 
Figure 33. Sphere filled with known activity. SPECT images were acquired and used to 
determine the absolute activity calibration factor for the scanner. 
 
6.3.3 In vivo Imaging Studies 
Three mice were injected with 18.5 MBq of 
67
Ga-DOTA-MC1RL in the syringe. 
SPECT/CT’s were acquired at 24, 48, and 96 hour timepoints. The CT datasets were 
downsampled to match the resolution of the SPECT datasets. The SPECT datasets were then 
manually registered to the CT datasets. ROI’s were drawn for the kidneys, liver and external on 
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the CT (Figures 34, 35, 36). The ROI extraction algorithm voxelized the ROI’s and converted 
them into a format readable by MCNP. 
 
Figure 34. Coronal CT slice of mouse with manually drawn kidneys and liver. The external 
contour was generated by thresholding. 
 
Figure 35. Kidneys and liver volumes in voxel coordinates. 
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Figure 36. Coronal views of SPECT/CT images acquired A) 24 hours, B) 48 hours, and C) 96 
hours post injection of 18.5 MBq of 
67
Ga-DOTA-MC1RL in SCID mice. 
 
The SPECT-based activity was determined by calculating the total activity in each ROI. These 
values were compared to whole organ activity measured in the ion chamber (Table 9). The image 
based activity calculations generally underestimated the ion chamber measurements. For the ion 
chamber kidney measurements it was assumed the activities of the left and right kidneys were 
equal as they were measured together.The average percent differences across all three timepoints 
for the right kidney, left kidney, liver, and body were 11.46 ± 3.31, 12.14 ± 3.26, 13.59 ± 6.03 , 
and 50.64 ± 10.42% respectively. The percent difference between the methods remained less 
than ~20% for the organs. The differences in total body activity estimations was large reaching 
up to 63% difference at the 96 hour timepoint. 
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Table 9. The SPECT derived ROI activities compared to organ activities measured using the ion 
chamber. 
24 hrs 
 
Kidney_R Kidney_L Liver Body 
SPECT Activity (kBq) 23.45 ± 10.81 22.44 ± 8.33 136.00 ± 9.49 254.02 ± 4.55 
IC Activity (kBq) 25.90 ± 2.59 25.90 ± 2.59 120.95 ±12.09 444.00 ± 4.44 
% Difference 9.48 13.38 12.44 42.79 
48 hrs 
 
Kidney_R Kidney_L Liver Body 
SPECT Activity (kBq) 17.93 ± 11.77 
13.28 ± 
10.68 
59.73 ± 9.25 166.24 ± 4.85 
IC Activity (kBq) 15.55 ± 1.55 15.55 ± 1.55 65.08 ± 6.51 311.73 ± 31.17 
% Difference 15.28 14.60 8.22 46.67 
96 hrs 
 
Kidney_R Kidney_L Liver Body 
SPECT Activity (kBq) 6.58 ± 9.97 5.50 ± 8.42 29.73 ± 9.51 150.67 ± 3.75 
IC Activity (kBq) 6.01 ± 0.60 6.01 ± 0.60 37.21 ± 3.72 401.45 ± 40.15 
% Difference 9.61 8.44 20.12 62.47 
 
The CT to MCNP conversion algorithm was performed on the three datasets. The defined 
materials were air, lung, fat, water, muscle, and bone. The SPECT to MCNP conversion 
algorithm was perfomed for the 
67
Ga-DOTA-MC1RL and the converted 
225
Ac-DOTA-MC1RL 
distributions for the three timepoints. Monte Carlo absorbed dose calculations were performed 
for the whole body for both radionuclides at each time point.
 
Voxelized organ absorbed dose 
simulations were also performed for 
225
Ac-DOTA-MC1RL considering only each specific organ. 
The converted CT, and corresponding slices of the resulting whole body absorbed dose 
distribution from 
67
Ga-DOTA-MC1RL and converted 
225
Ac-DOTA-MC1RL can be seen in 
Figure 37. 
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Figure 37. For 24, 48, and 96 hours: A) Mouse-specific phantom obtained from CT. B) Absorbed 
dose map for 
67
Ga-DOTA-MC1RL. C) Corresponding absorbed dose map for 
225
Ac-DOTA-
MC1RL. Note the difference in scales. Spatial dimensions are in centimeters. 
A) B) C) 
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The mean whole body absorbed dose for 
67
Ga-DOTA-MC1RL was 2.6085E-06 mGy/MBq. This 
underestimated the MIRD calculated whole body dose of 4.9E-04 mGy/MBq. 
Mean absorbed doses for the right kidney and liver were calculated. Voxelized dose maps for 
67
Ga-DOTA-MC1RL and 
225
Ac-DOTA-MC1RL can be seen in Figure 38. 
 
Figure 38. Absorbed dose maps for 
67
Ga-DOTA-MC1RL in the right kidney at 24, 48, and 96 
hour time points and corresponding dose maps for 
225
Ac-DOTA-MC1RL. The spatial dimensions 
are in centimeters. 
   
The dose rates were fitted with an exponential regression and integrated to obtain the total 
absorbed dose to the kidney from 
67
Ga-DOTA-MC1RL and 
225
Ac-DOTA-MC1RL (Figure 39). 
The mean absorbed dose to the right kidney from 
67
Ga-DOTA-MC1RL was calculated to be 
0.0084 ± 0.0022 mGy/MBq. Using the MIRD schema, the mean absorbed dose to the right 
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kidney was found to be 0.0079 ± 0.0016 mGy/MBq (Figure 30). The same procedure was 
performed to calculate the mean dose from 
225
Ac-DOTA-MC1RL to the right kidney.  
 
Figure 39. Exponential fitting of the mean dose rate as a function of time for 
225
Ac-DOTA-
MC1RL in the right kidney. 
 
The mean absorbed dose to the right kidney was calculated to be 0.0213 ± 0.0082 Gy/kBq. Using 
the MIRD schema, the mean absorbed dose to the right kidney was found to be 0.0150 ± 0.0031 
Gy/kBq (Table 5). The DVH for the kidney can be seen in Figure 40. 
 
Figure 40. Dose volume histogram for 
225
Ac-DOTA-MC1RL in the right kidney. 
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The absorbed dose maps for the left kidney can be seen in Figure 41. 
 
Figure 41. Absorbed dose maps for 
67
Ga-DOTA-MC1RL in the left kidney at 24, 48, and 96 
hour time points and corresponding dose maps for 
225
Ac-DOTA-MC1RL. The spatial dimensions 
are in centimeters. 
 
The dose rates were fitted with an exponential regression and integrated to obtain the total 
absorbed dose to the left kidney from 
67
Ga-DOTA-MC1RL and 
225
Ac-DOTA-MC1RL (Figure 
42). The mean absorbed dose to the left kidney from 
67
Ga-DOTA-MC1RL was calculated to be 
0.0075 ± 0.0011 mGy/MBq. This is compared to the MIRD calculated dose of 0.0079 ± 0.0016 
mGy/MBq.  
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Figure 42. Exponential fitting of the mean dose rate as a function of time for 
225
Ac-DOTA-
MC1RL in the left kidney. 
 
Similarly, the voxel-based mean absorbed dose was calculated for 
225
Ac-DOTA-MC1RL 
resulting in 0.0110 ± 0.0002 Gy/kBq as compared to 0.0150 ± 0.0031 Gy/kBq found 
conventionally.  The DVH can be seen in Figure 43. 
 
 
Figure 43. Dose volume histogram for 
225
Ac-DOTA-MC1RL in the left kidney. 
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Absorbed dose maps for the liver can be seen in Figure 44.
 
Figure 44. Absorbed dose maps for 
67
Ga-DOTA-MC1RL in the liver at 24, 48, and 96 hour time 
points and corresponding dose maps for 
225
Ac-DOTA-MC1RL. The spatial dimensions are in 
centimeters. 
 
The mean organ absorbed dose to the liver was calculated for 
67
Ga-DOTA-MC1RL and 
225
Ac-
DOTA-MC1RL by fitting the dose at each timepoint with an exponential fit and integrating 
(Figure 45). 
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Figure 45. Exponential fitting of the mean dose rate as a function of time for 
225
Ac-DOTA-
MC1RL in the liver. 
 
The total absorbed dose to the liver from 
67
Ga-DOTA-MC1RL was 0.0016 ± 0.0001 mGy/MBq. 
The MIRD calculated absorbed dose was 0.0031 ± 0.0006 mGy/MBq. The resulting absorbed 
dose from 
225
Ac-DOTA-MC1RL was found to be 0.0633 ± 0.0082 Gy/kBq compared to 0.1485 
± 0.0283 Gy/kBq. The dose volume histogram for the absorbed dose in the liver can be seen in 
Figure 46. 
 
Figure 46. Dose volume histogram for 
225
Ac-DOTA-MC1RL in the liver. 
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6.4 Discussion 
In this work a method was developed to calculate the absorbed radiation dose at the voxel 
level for a targeted alpha particle therapy. The companion imaging agent, 
67
Ga-DOTA-MC1RL, 
was developed and tested and compared to the therapeutic agent. Other groups have developed 
and used companion imaging agents to perform image-based dosimetry for alpha emitting 
radiopharmaceuticals. For example, the 
68
Ga/
225
Ac-Prostate-specific membrane antigen-617 
(PSMA-617) 
70
, the 
203
Pb/
212
Pb-DOTA-MC1L
71
, and the  
99m
Tc-methyl diphosphonate/
223
Ra-
dichloide
69
 pairs have been used in dose calculations for the targeted alpha therapy of metastatic 
castration resistant prostate cancer, metastatic melanoma, and bone metastases respectively. 
While this approach results in patient specific prediction of the biodistribution and 
pharmacokinetics of the targeted alpha therapy, the treatment planning will be suboptimal. 
OLINDA is a model based approach using pre-calculated S factors obtained from a fixed 
geometry phantom to calculate mean organ level absorbed dose. 
The spectrum fitting algorithm was updated for 
67
Ga-DOTA-MC1RL biodistribution 
analysis using the Monte Carlo detector model that was previously developed. The BD of a 
companion imaging agent should ideally mimic the BD of the therapeutic agent in order to 
implement a treatment planning procedure. The BD of 
67
Ga-DOTA-MC1RL and 
225
Ac-DOTA-
MC1RL showed that these agents distribute differently throughout the body. At 24 hours, 
67
Ga-
DOTA-MC1RL showed increased uptake into the kidneys with slightly lower uptake in the liver. 
This is much different than the liver uptake of 
225
Ac-DOTA-MC1RL which was shown to be 
nearly 3.5 times greater than kidney uptake at 24 hours. Despite this difference, there was some 
uptake into intestine, lungs, and spleen and minimal uptake into other tissues for both 
67
Ga-
DOTA-MC1RL and 
225
Ac-DOTA-MC1RL.  Dosimetry estimates were performed based on the 
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67
Ga-DOTA-MC1RL BD using the MIRD methodology and fixed geometry S values. Since 
67
Ga 
is a gamma emitter, the assumption that cross organ dose contribution is negligible fails. Using 
the S values generated from the standard mouse phantom it was found that the mean dose to the 
kidneys was over 5 times greater than the dose to the liver. This is in contrast with the 
225
Ac-
DOTA-MC1RL calculated dose to the liver which was nearly 5 times greater than the dose to the 
kidneys. This discrepancy can be accounted for by applying a factor that corrects the 
67
Ga-
DOTA-MC1RL biodistribution to that of the therapeutic. 
 Using the EDP phantom, an algorithm was created that converted acquired CT images 
into the MCNP lattice geometry. An algorithm was created that voxelized the segmented ROI’s 
drawn around the TMM’s. The EDP phantom has 13 TMM’s however only 6 materials were 
modeled in this work. This was necessary because of the complexity of the image derived 
geometries and computationally expensive tracking of charged particles through different 
materials.  
The absolute activity calibration factor was obtained by applying the ROI algorithm to a 
spherical phantom filled with 
67
Ga in air. As a result, the SPECT based organ activity 
estimations could be compared to ion chamber based whole organ measurements. The image 
based activity estimations for the liver and kidneys agreed with the IC measurements well. The 
whole body estimates however were not in agreement with IC measurements with percent 
differences of up to ~60%. At all three time points the image based whole body activities 
underestimated the ion chamber. A first step to address these differences would be to fill the 
spherical phantom with pure 
67
Ga instead of the whole 
67
Ga-DOTA-MC1RL compound. This 
would allow for uniform activity distribution 
67
Ga in the phantom and avoid aggregation of the 
solution as seen in Figure 33. 
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Voxelized absorbed dose maps were successfully generated from the in vivo CT and 
SPECT datasets. The whole body absorbed doses did not correlate well with the MIRD 
calculations. This was to be expected given the large discrepancies in the image-based activity 
estimates and ion chamber measurements. Also, in the conventional calculation of total body 
absorbed doses, the assumption is made that the activity not used for organ calculation activity is 
uniformly distributed throughout the remainder of the body
164
.The doses calculated for the 
kidneys and liver on the other hand agreed with MIRD calculations to within an order of 
magnitude for both 
67
Ga-DOTA-MC1RL and 
225
Ac-DOTA-MC1RL. This suggests that the 
developed methodology is valid. Discrepancies are likely the result of the many sources of error 
in the methodology. The major source is error in activity estimation. ROI’s were drawn manually 
on downsampled CT datasets that were manually registered to SPECT datasets. Since the mice 
were sacrificed after imaging for tissue harvesting, each timepoint involved a single different 
mouse. To reduce error, serial images the same mouse with multiple mice per timepoint should 
be performed. 
It is evident from the voxel based dose calculations that the uptake of 
67
Ga-DOTA-
MC1RL in the liver and kidneys is not uniform. In the case of the kidney, the dose accumulated 
more in the outer cortex region. Using the conventional dosimetry formalism, it is not possible to 
observe this result. DVH plots are one of the most utilized tools in external beam therapy to 
evaluate treatment plan quality. DVH’s were generated for ROI’s with the developed voxelized 
methodology enabling capability of volumetric analysis. 
Due to the complexity of performing patient specific internal dosimetry, clinical 
applications have been limited. Several other voxel-based platforms have been developed, 
however the fixed geometry software OLINDA remains the only FDA approved system
48
. The 
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most notable voxel-based systems include 3DRD
57
, SCMS
56
, DPM
165
, VIDA
166
, and RAPID
61
. 
Similarly to the work presented in this thesis, all of these systems have been benchmarked 
against conventional calculations and show good agreement. These systems use the point kernel 
convolution method for Monte Carlo simulation and therefore don’t account for tissue 
heterogeneities. This method was chosen to make these systems more clinically applicable by 
speeding up the calculation, however, none have seen wide acceptance for clinical use. The 
methodology developed in this thesis performs full Monte Carlo calculations by tracking all 
relevant particles accounting for material compositions. The length of time to perform a full dose 
calculation, including all pre and post processing, at a single time point takes ~30 hours. This is 
faster than the all the aforementioned platforms. This is noteworthy because these platforms have 
mostly been used for photon dose calculations, while the methodology developed here tracks and 
tallies not only alpha particles, but delta rays and resulting bremsstrahlung productions. While 
several fundamental aspects of the methodology developed here align with these systems, this is 
the only one specifically designed to perform targeted alpha therapy dosimetry. 
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CHAPTER SEVEN: 
CONCLUSIONS 
 
In this work, an alpha emitting radiopharmaceutical was thoroughly assessed. Methods 
for improving the accuracy of alpha particle radioactivity determination were developed. This is 
important for pharmacokinetic evaluation and patient safety as many aspects of activity 
measurement have been overlooked both pre-clinically and clinically. The alpha therapeutic, 
225
Ac-DOTA-MC1RL, was tested in several experiments and was shown to have low toxicity, 
rapid blood clearance, uptake into MC1R positive tumors and clearance organs, significant tumor 
and metastasis growth delay, and prolonged survival in human uveal melanoma xenograft 
models in mice following a single administration. Conventional radiation dosimetry analysis 
showed 10x greater absorbed doses in high MC1R expressing tumors than in low MC1R 
expressing tumors as well as low doses to non-clearance organs. A multi-compartment 
pharmacokinetic model was developed with the aim of increasing the personalization of the 
treatment by optimizing administration activities for the patient and predicting biodistribution 
through the use of a companion imaging agent. Ultimately, the goal of this work was to develop 
a patient specific image based dosimetric methodology for 
225
Ac-DOTA-MC1RL treatment 
planning. Most therapeutic radiopharmaceutical therapies use fixed administrations with no 
personalization. A companion imaging agent, 
67
Ga-DOTA-MC1RL was developed and tested. 
67
Ga-DOTA-MC1RL has somewhat similar biodistribution to 
225
Ac-DOTA-MC1RL allowing 
 106 
for the visualization and prediction of the spatial and temporal distribution that the therapeutic 
will have. By acquiring several SPECT images post administration of 
67
Ga-DOTA-MC1RL, 
cumulated voxelized activity maps can be generated, converted to 
225
Ac-DOTA-MC1RL activity 
and submitted for Monte Carlo dose calculation. The result is a voxelized 3D absorbed dose 
distribution. This information can then be used to optimize a treatment plan for patients with the 
goal of improving their outcome.  
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